Language

I am a radiation oncologist treating a broad range of cancers, with a special focus on genitourinary and gastrointestinal cancers. My research examines molecular and clinical biomarkers, radiation toxicity and oncology data science.

Academic profile Full CV

Portrait of Konrad Stawiski
Portrait of Konrad Stawiski
60journal articles
282.9cumulative Impact Factor
5,844Polish ministerial points
826citations in Scopus (782 in Web of Science)
16h-index in Scopus and Web of Science
19h-index in Google Scholar (1,169 citations)

Articles, Impact Factor, points, Scopus and Web of Science: Library and Information Centre, Medical University of Lodz, as of 13 October 2026; Google Scholar: as of 7 November 2026.

Summary

Konrad G. Stawiski is a board-certified radiation oncologist and Deputy Head of the 34-bed Brachytherapy and General Oncology Department at Copernicus Memorial Hospital in Lodz. He is an Assistant Professor at the Medical University of Lodz and a Research Specialist (post-doc) in STOPSTORM.eu at the National Institute of Oncology, Gliwice Branch. In 2026, he held a funded visiting appointment as Visiting Assistant Professor of Radiation Oncology at Dana-Farber Cancer Institute and Harvard Medical School.

His research showed that greater tumour memory B-cell infiltration is associated with longer survival after platinum chemotherapy in advanced urothelial carcinoma, mainly in cisplatin-treated patients (HR 0.19; 95% CI 0.05–0.75). During rectal cancer radiochemotherapy, routine lymphocyte counts, age and sex predicted severe lymphopenia, and dosimetry did not improve that prediction. He also evaluated circulating microRNA signals before ovarian cancer diagnosis and developed a protocol for prioritising tumour-only sequencing variants for review.

Google Scholar lists 96 records, including conference abstracts, preprints and patents, with an h-index of 19 and 1,169 citations. His record includes two circulating microRNA patent families, leadership of the Polish group and Work Package 4 in ERA PerMed miRPOC, completed NCN PRELUDIUM and Radonek-AI projects, and work as a Sub-Investigator in phase II–III oncology trials. He develops research software, supervises students and serves on the BMC Cancer Editorial Board.

Employment history

  • From 7 January 2025: Research Specialist (post-doc), STOPSTORM.eu, National Institute of Oncology (Maria Skłodowska-Curie), Gliwice Branch. Work Package 5: registry analysis and analysis planning; predictive modelling of treatment outcomes; cardiac normal-tissue complication probability (NTCP) modelling; automatic cardiac segmentation, dose estimation and radiomic biomarkers.
  • 2024–present: Assistant Professor, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland.
    • Supervisor of the “Artificial Intelligence in Oncology” Students’ Scientific Group.
    • Lecturer in Biostatistics, Translational Medicine, Research Methodology, and AI, including data mining and deep learning.
    • Cancer research using bioinformatics and omics data analysis (radiomics, next-generation sequencing: miRNA-seq, bulk and single-cell RNA-seq, and whole-exome sequencing).
    • Polish group lead in the ERA PerMed miRPOC international consortium.
  • 2023–present: Radiation Oncologist, Deputy Head of Department of Brachytherapy and General Oncology, Regional Oncology Centre, Copernicus Memorial Hospital, Lodz, Poland.
    • Deputy clinical lead for a 34-bed ward, coordinating external-beam radiotherapy, brachytherapy, concurrent chemoradiotherapy and general oncology inpatient care.
  • 2021–2023: Research and Teaching Assistant, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland.
  • 2018–2023: Radiation Oncology Resident Physician, Regional Oncology Centre, Copernicus Memorial Hospital, Lodz, Poland.
    • Physician in Department of Radiotherapy and on-call physician in Radiotherapy and Oncology Ward (reference: Prof. Jacek Fijuth, M.D., Ph.D.).
    • Additional experience as on-call physician in Haemato-oncology Ward (reference: Prof. Piotr Smolewski, M.D., Ph.D.).
  • 2017–2018: Bioinformatics and Medical Informatics Specialist, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland.
  • 2016–2017: Medical Post-graduate Internship, Clinical Hospital of the Ministry of the Interior and Administration in Lodz, Lodz, Poland.

Visiting academic appointments

These research stays were funded by the Polish National Agency for Academic Exchange (NAWA) and hosted by Dana-Farber Cancer Institute while he remained employed by the Medical University of Lodz.

  • 1 February–31 July 2026: Visiting Assistant Professor of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA. Prof. Franciszek Walczak NAWA Programme, BPN/WAL/2024/1/00014; host: Kent W. Mouw. Project: “Integrated Multi-Modal Predictors of Response and Long-Term Survival in Muscle-Invasive Bladder Cancer Treated with Bladder-Sparing Trimodality Therapy”. Institutional scholarship report.
  • 1 August 2022–1 February 2023: Research Fellow in Radiation Oncology, Dana-Farber Cancer Institute; research environment including Harvard Medical School and the Broad Institute of MIT and Harvard, Boston, USA. Mieczysław Bekker NAWA Programme, BPN/BEK/2021/1/00065; host: Kent W. Mouw (Mouw Lab), working with Filipe L.F. Carvalho’s team (Carvalho Lab). Project on gene-expression interplay between radiotherapy and concurrent immunotherapy in muscle-invasive bladder cancer.

Clinical practice

Broad radiotherapy practice with a special focus on genitourinary and gastrointestinal cancers, especially prostate, bladder and rectal cancer; also central nervous system, lung, oesophageal and haematological malignancies. Treatment includes external-beam radiotherapy, brachytherapy, stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), radiochemotherapy and radioimmunotherapy, including prostate radiotherapy, bladder-preserving trimodality treatment and rectal cancer chemoradiotherapy.

Multidisciplinary uro-oncology care. Member of multidisciplinary tumour boards within the DiLO fast-track oncology pathway at Copernicus Memorial Hospital (Lung Cancer Unit), N. Barlicki University Hospital No. 1 and Military Medical Academy University Hospital No. 2 in Lodz. Haemato-oncology duty experience includes care of patients with myeloma, lymphoma and leukaemia during residency. Clinical information.

Clinical trials

Sub-Investigator in commercial and non-commercial clinical trials at the Copernicus centre in Lodz, including all five studies below, with responsibilities for protocol treatment, response and safety assessment, and treatment documentation.

  • TALAPRO-2 (C3441021; NCT03395197): phase 3 trial of talazoparib plus enzalutamide versus enzalutamide monotherapy in metastatic castration-resistant prostate cancer.
  • KEYNOTE-867 (MK-3475-867; NCT03924869): phase 3 randomised placebo-controlled trial of SBRT with or without pembrolizumab in unresected stage I or II non-small-cell lung cancer.
  • KEYNOTE-689 (MK-3475-689; NCT03765918): phase 3 randomised open-label trial of pembrolizumab as neoadjuvant therapy and with standard care as adjuvant therapy in stage III–IVA resectable locoregionally advanced head and neck squamous cell carcinoma.
  • CALLA (D9100C00001; NCT03830866): phase 3 trial of durvalumab with chemoradiotherapy in women with locally advanced cervical cancer.
  • NC-6004-009 (NCT03771820): phase IIa/IIb trial of NC-6004 with pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma after platinum failure.

Education

  • 4 August 2023: Board Certification in Radiation Oncology, Medical Examinations Center (CEM) in Poland.
  • 26 October 2021: Doctor of Philosophy (PhD) (doctoral studies 2016–2021), Department of Biostatistics and Translational Medicine, Medical University of Lodz (supervisor: Prof. Wojciech Fendler):
    • Dissertation: Głębokie sztuczne sieci neuronowe w integracji profilu ekspresji krążących i wewnątrzkomórkowych cząsteczek miRNA pacjentów z rakiem trzustki. (Deep learning-based integration of circulating and cellular miRNA expression of pancreatic cancer.) (NCN project description)
  • 2017: Full medical licence in Poland (PWZ: 3347648).
  • 2010–2016: Doctor of Medicine (MD) (6-year M.D. programme; diploma awarded 10 June 2016; grade: very good), Faculty of Medicine, Medical University of Lodz (Poland).

Internships

  • 8 July–7 September 2016: ERASMUS+ research internship at the EPSRC Centre for Mathematical and Statistical Analysis of Multimodal Clinical Imaging, University of Cambridge, Cambridge, UK, focused on real-time TRUS-MRI fusion software for prostate cancer biopsy (reference: Prof. John Aston, Ph.D.).
  • 6 July–14 August 2015: IFMSA research exchange (6 weeks), Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Upstate Medical University, Syracuse, NY, USA (reference: Stephen J. Glatt, Ph.D.).
  • 2014: Neurosurgical clinical clerkship (3 weeks), University Hospital Southampton NHS Trust, Southampton, UK (reference: Paul Grundy, M.D.).
  • 2013: Medical clinical clerkship (4 weeks), Mubarak Al Kabeer Hospital, Kuwait City, Kuwait (reference: Ibrahim T. Lasheen, M.D.).

Research

Key research series

Trustworthy interpretation of molecular and clinical biomarkers in oncology. These four papers examine the conditions under which a measured signal retains diagnostic, prognostic or interpretive value.

MicroRNA signals before ovarian cancer diagnosis

Does a circulating microRNA signature distinguish samples taken closer to diagnosis? In an exploratory study of 80 women who later developed invasive epithelial ovarian cancer, a 14-miRNA model distinguished serum samples collected less than two years before diagnosis from those collected two to seven years before diagnosis (median test-set area under the ROC curve [AUC] 0.771 versus 0.587 for random 14-miRNA sets). This comparison was within women who later developed cancer, so it was not a test of detection; the finding supports prospective evaluation with cancer-free controls.

Role: equal first and corresponding author; analysis methods, machine-learning models and validation, time-to-diagnosis expression analyses and software. Frontiers in Oncology, 2024.

Memory B cells and survival in advanced urothelial cancer

Does the immune-cell composition of the tumour carry prognostic information during platinum chemotherapy? In 189 patients from three cohorts receiving first-line platinum chemotherapy alone, greater tumour lymphocyte infiltration was associated with longer overall survival (HR 0.34; 95% CI 0.16–0.72), with the strongest association for memory B cells (HR 0.19; 95% CI 0.05–0.75), mainly in cisplatin-treated patients, whereas myeloid infiltration was associated with shorter survival. This is a prognostic association, not evidence for choosing a drug, and supports studying B cells and tertiary lymphoid structures as prognostic biomarkers.

Role: equal first author; study concept and design, bioinformatics and statistics with Júlia Perera-Bel, interpretation, joint drafting and funding acquisition. Molecular Oncology, 2026.

Lymphopenia risk during rectal cancer radiochemotherapy

Can routine blood counts predict severe lymphopenia, and does dosimetry improve prediction? Among 179 patients, severe lymphopenia occurred in 76 of 173 with an evaluable nadir (44%). A model of baseline lymphocyte count (measured up to 60 days before and, in some patients, up to 7 days after radiotherapy began), age and sex reached an optimism-corrected concordance index of 0.746; adding inflammatory markers or dosimetry did not improve prediction. Severe lymphopenia was not associated with tumour response, and its apparent favourable survival association based on nadir (HR 0.22; 95% CI 0.07–0.64) disappeared in a time-dependent analysis (HR 0.93; 95% CI 0.34–2.53). A potential use is directing supportive care to high-risk patients; use at other centres requires external validation, including clinical utility.

Role: first and corresponding author; concept, methods, data preparation, statistics, software, visualisation and manuscript drafting. International Journal of Radiation Oncology, Biology, Physics, 2026.

Interpretable review of tumour-only sequencing variants

Can explicit evidence rules prioritise variants when matched normal tissue is unavailable? In the SEQC2 HCC1395 reference dataset, the highest Somatic Likelihood Tiering category (SLT-A) held 78 true somatic variants among 101 candidates (positive predictive value 77.2%; 95% CI 68.1–84.3%), and categories SLT-A to SLT-C retained 352 of 455 reference variants (77.4%). SLT-A contained 18.2% of the variants found by matched-normal analysis in the urothelial cohort HdM-BLCA-1 and 49.1% in the lung adenocarcinoma cohort LUAD-TW (recovery assessed in 32 of 113 patients); these figures measure agreement with matched-normal analysis, not diagnostic accuracy. With a small normal-sample panel from another batch, SLT-A and SLT-B together recovered only 8.3% of reference variants in COLO829 and 12.6% in NCI-H1770, so transfer requires a panel matched to the laboratory workflow. The protocol records why each variant is prioritised for review and does not replace matched-normal sequencing.

Role: first and corresponding author; concept, rules, software, comparative analyses, interpretation and manuscript. Briefings in Bioinformatics, 2026.

Research collaborations

  • Kent W. Mouw and Filipe L.F. Carvalho teams at Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School: bladder cancer genomics, immune microenvironment, treatment resistance and organ preservation, within the research environment of the Broad Institute.
  • Kevin M. Elias and Dipanjan Chowdhury teams: circulating microRNA in ovarian cancer, BRCA1/2 carrier identification and cancer risk; collaboration with the PREDICT consortium, Cancer Registry of Norway and German Cancer Research Center.
  • Medical University of Vienna (S.F. Shariat, P. Rajwa) and Torino School of Medicine (F. Soria): recurrence and progression models in non-muscle-invasive bladder cancer.
  • Medical University of Silesia and National Institute of Oncology, Gliwice Branch: prognostic factors in prostate radiotherapy, brachytherapy boost and postoperative radiotherapy.
  • European STOPSTORM.eu and ERA PerMed partners: cardiac radioablation and ovarian biomarker research. A further research line concerns circulating biomarkers of radiation exposure and toxicity, lymphopenia in lung and rectal cancer, bone-marrow dose and haematological toxicity, including myeloma treatment.

Research grants, funded projects and innovation work

  • STOPSTORM.eu, EU Horizon 2020, grant 945119; Research Specialist (post-doc) at the National Institute of Oncology, Gliwice Branch, from 7 January 2025. Consortium coordinator: University Hospital Schleswig-Holstein, Kiel. Work Package 5: analysis of the prospective European cohort of stereotactic arrhythmia radioablation, analysis plan, predictive modelling, cardiac NTCP models, automatic cardiac segmentation, dose estimation and radiomic biomarkers.
  • miRPOC – miRNA as biomarkers in early detection and personalized treatment in ovarian cancer. ERA PerMed Joint Transnational Call 2022, ERAPERMED2022-073; National Centre for Research and Development, PerMed/V/7/miRPOC/2024. 1 October 2023–30 September 2027; Partner PI, Polish group lead and Work Package 4 lead. Polish partner budget PLN 752,098.75; consortium budget EUR 740,194. Biomarker-model development and evaluation, and molecular-data analysis. Partners: Oslo University Hospital / Cancer Registry of Norway (coordinator), German Cancer Research Center, Brigham and Women’s Hospital / Harvard Medical School, and Medical University of Lodz.
  • Radonek-AI – virtual oncology patient assistant. Student Scientific Circles Create Innovations programme, fourth edition, Polish Ministry of Science and Higher Education; SKN/SP/601573/2024. 15 June 2024–15 December 2025; PI; PLN 70,000. Patient communication and information tool, with scientific supervision of the student team.
  • Deep artificial neural networks integrating circulating and intracellular miRNA profiles in pancreatic cancer, National Science Centre (NCN), PRELUDIUM 15; UMO-2018/29/N/NZ5/02422. 21 March 2019–20 December 2022; PI; PLN 209,860. Molecular-data integration underpinning the doctoral dissertation.
  • Predictive Biomarkers of Radiation Toxicity (PBRTox), Foundation for Polish Science, FIRST TEAM; POIR.04.04.00-00-2280/16. Project 1 May 2017–31 October 2021, participation 2019–2021; researcher, PI Prof. Wojciech Fendler. Initial budget PLN 1,999,651; final project budget PLN 2,594,726. Circulating biomarkers of radiation exposure and radiotherapy toxicity.
  • Lodz Programme for Head and Neck Cancer Prevention, Operational Programme Knowledge Education Development, co-financed by the European Social Fund; POWR.05.01.00-00-0011/16-00. Project 1 October 2017–30 September 2021, participation 2017–2018; bioinformatics and medical informatics specialist; PLN 1,792,260. Web platform for programme and research data collection.
  • Circulating microRNA profiles in the diagnosis of rare forms of diabetes, NCN SONATA BIS 1; 2012/05/E/NZ5/02130. Project 25 January 2013–24 July 2017, participation 2014–2016; researcher, PI Prof. Wojciech Fendler; PLN 1,489,800. Molecular-data analysis and bioinformatics in biomarker research.
  • PancreApp, Generation of the Future programme, Polish Ministry of Science and Higher Education; MNiSW/2014/DIR/379/GPII. 2014–2015; PI; PLN 37,800. Eight-dimensional Shepard approximation for individualised nutritional recommendations, particularly in chronic pancreatitis.

Awards, honours and scholarships

  • 2025: Prof. Franciszek Walczak NAWA Programme Scholarship, Polish National Agency for Academic Exchange; one of 31 awardees selected from 125 applications in the 2024 edition (NAWA results; decision in June 2025; 25% success rate), for a 6-month Dana-Farber / Harvard Medical School fellowship on bladder-preserving treatment strategies in muscle-invasive bladder cancer; institutional report: application score 94/100.
  • 2025: First place for final research project in the Harvard Medical School / Polish Medical Research Agency Clinical Scholars Research Training programme, for a project on rectal cancer radiochemotherapy.
  • 2022: Rector’s Award for Research Achievements in 2021, Medical University of Lodz, team award for publication series on urological cancer (12.919 IF).
  • 2022: Best biostatistics Ph.D. thesis in 2021 (awarded by StatSoft Polska).
  • 2022: Team Award of the Polish Minister of Health, jointly with Prof. Wojciech Fendler, for implementing a diagnostic test based on circulating microRNA into clinical practice.
  • 2021: Mieczysław Bekker NAWA Programme scholarship, BPN/BEK/2021/1/00065, supporting the research stay in Boston in 2022–2023.
  • 2021: Scholarship of Polpharma Scientific Foundation for best Ph.D. students, awarded for the dissertation on deep artificial neural networks integrating circulating and intracellular miRNA profiles in pancreatic cancer.
  • 2020: Scholarship for the best Ph.D. students at the Medical University of Lodz.
  • 2019: Scholarship for the best Ph.D. students at the Medical University of Lodz.
  • 2018: Scholarship for the best Ph.D. students at the Medical University of Lodz.
  • 2017: Scholarship for the best Ph.D. students at the Medical University of Lodz.
  • 2016: Scholarship for the best Ph.D. students at the Medical University of Lodz.
  • 2016: Scholarship of the City of Lodz for the best Ph.D. students.
  • 2016: Winner of Adzuna’s Polish “Graduate of the Year” contest.
  • 2015: Scholarship of Minister of Science and Higher Education & Minister of Health of Republic of Poland for outstanding achievements for students in the academic year 2015/2016.
  • 2015: Scholarship of Marshal of the Lodzkie Region (highest degree).
  • 2014: Distinction in a nationwide competition “Studencki Nobel” (Eng. “Student’s Nobel Prize”).
  • 2014: Special Award for the Youngest Winner of the Session at the conference 10. International & 52. Polish Training & Scientific Medical Congress of Students’ Scientific Societies and Junior Doctors “Juvenes Pro Medicina” 2014 in Lodz (founder: Aldona Ochęcka-Szymańska, M.D., Ph.D.).
  • 2013: Scholarship of Minister of Science and Higher Education of Republic of Poland for outstanding achievements for students in the academic year 2013/2014.

Patents and commercializations

Circulating microRNA signatures for ovarian cancer. Inventors: Dipanjan Chowdhury, Kevin M. Elias, Wojciech Fendler and Konrad Stawiski. Assignees: Medical University of Lodz, The Brigham and Women’s Hospital, Inc., and Dana-Farber Cancer Institute, Inc.

Circulating microRNA signatures for pancreatic cancer. Inventors: Dipanjan Chowdhury, Wojciech Fendler and Konrad Stawiski. Applicants: Medical University of Lodz and Dana-Farber Cancer Institute, Inc. Patent-application family; priority 9 July 2021. International application PCT/US2022/036608, filed 9 July 2022, published as WO2023283476A2 on 12 January 2023. National and regional application publications: CA3223723A1, AU2022306397A1, US20250092460A1, EP4367257A2, JP2024527370A.

Commercialisation. The ovarian cancer family was licensed to Aspira Women’s Health Inc. on 20 March 2023. The circulating microRNA signature is a component of the company’s OVAinform test (formerly OvaMDx). Sponsored research since August 2022 concerns the non-invasive endometriosis test ENDOinform (formerly EndoMDx), based on circulating microRNA and proteins. Konrad Stawiski is responsible for statistical analyses and classification models in the Medical University of Lodz team, working with Dana-Farber Cancer Institute and Brigham and Women’s Hospital.

Publications

Bibliometrics

The 60 articles comprise 54 original papers, 3 meta-analyses, 2 reviews and 1 case report. First or equal first author of at least 10 articles and corresponding author of 5.

Period Articles Cumulative Impact Factor Ministerial points
After the doctorate 38 193.517 4,150
Before the doctorate 22 89.383 1,694
Total 60 282.900 5,844
Database Citations Excluding self-citations h-index
Web of Science Core Collection 782 758 16
Scopus 826 801 16

Library and Information Centre, Medical University of Lodz, as of 13 October 2026. Impact Factor and ministerial points of the publication year; for 2026 papers the latest available Impact Factor (2025). Split by date of final publication; the doctorate was conferred on 26 October 2021.

H-index according to Google Scholar: 19
(citations = 1,169; records = 96)
Citations by year and publication records by year from the curated Google Scholar data.

Citations by year and publication records by year from the curated Google Scholar data.

For formal publication review, use PubMed, ORCID, and OpenAlex as authoritative records.

International collaboration network

OpenAlex currently identifies publication coauthors affiliated with 14 countries outside Poland. Coauthored works by country: United States (50), United Kingdom (7), Greece (5), Austria (4).

World map of publication coauthor-affiliation countries, with Poland outlined as the home base and countries shaded by coauthored work count.

The map shows coauthor-affiliation countries recorded in OpenAlex Works; it describes publication collaboration, not formal institutional agreements.

Selected publications and contributions

  • Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma. Molecular Oncology. 2026;20(9):2340–2355. doi: 10.1002/1878-0261.70276. Role: Equal first author; concept and design, bioinformatics and statistics with Júlia Perera-Bel, interpretation, joint drafting and funding acquisition.

  • Stawiski K, Nowicka Z, Burzyński J, Jędrzejczak N, Zięba A, Sławiński L, Peszyńska-Piorun M, Mouw KW, Masłowski M, Fendler W. Baseline lymphocyte count outperforms dosimetry and inflammatory markers for predicting severe radiation-induced lymphopenia in rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 2026. doi: 10.1016/j.ijrobp.2026.08.034. Role: First and corresponding author; concept, methods, data preparation, statistics, software, visualisation and manuscript.

  • Stawiski K, Kamran SC, Perera-Bel J, Lee J, Bellmunt J, Mouw KW, De Carvalho FLF. Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review. Briefings in Bioinformatics. 2026;27(5):bbag487. doi: 10.1093/bib/bbag487. Role: First and corresponding author; protocol, software, comparative analyses, interpretation and manuscript.

  • Zhou Y, Börcsök J, Adib E, Kamran SC, Neil AJ, Stawiski K, Freeman D, Stormoen DR, Sztupinszki Z, Samant A, Nassar A, Bekele RT, Hanlon T, Valentine H, Epstein I, Sharma B, Felt K, Abbosh P, Wu CL, Efstathiou JA, Miyamoto DT, Anderson W, Szallasi Z, Mouw KW. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Science Advances. 2023;9(47):eadg2263. doi: 10.1126/sciadv.adg2263. Role: Co-author in translational bladder cancer research.

  • Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Różański W, Soria F, Shariat SF, Fendler W. Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. European Urology Oncology. 2022;5(1):109–112. doi: 10.1016/j.euo.2021.05.006. Role: Equal first and corresponding author; clinical prediction modelling.

  • Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczyński A, et al. OmicSelector: automatic feature selection and deep learning modeling for omic experiments. bioRxiv. 2022. doi: 10.1101/2022.06.01.494299. Role: First author and software lead; preprint.

  • Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, Elias KM, Fendler W, Langseth H. Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches. Frontiers in Oncology. 2024;14:1389066. doi: 10.3389/fonc.2024.1389066. Role: Equal first and corresponding author; machine-learning methods, model validation, expression analyses and software.

  • Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, Frendl G, Konstantinopoulos P, Crum CP, Kedzierska M, Cramer DW, Chowdhury D. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. eLife. 2017;6:e28932. doi: 10.7554/eLife.28932. Role: Model software and data analysis.

  • Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, Ussowicz M, Chowdhury D, Fendler W. Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study. Radiotherapy and Oncology. 2023;185:109731. doi: 10.1016/j.radonc.2023.109731. Role: Co-author in radiation biomarker research.

  • Nowicka Z, Kuna K, Łaszczych M, Łazar-Poniatowska M, Sobocki BK, Stawiski K, Dąbrowski M, Bruski K, Zięba A, Pajdziński M, Staniewska E, Miszczyk M, Paganetti H, Fendler W, Tomasik B. Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques. Physics and Imaging in Radiation Oncology. 2024;30:100593. doi: 10.1016/j.phro.2024.100593. Role: Co-author in radiotherapy data analysis and prediction modelling.

Journal articles (60)

2026

  1. Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma. Molecular Oncology. 2026;20(9):2340–2355. doi:10.1002/1878-0261.70276 PMID 42226382 PreprintEqual first authorKey research series
  2. Stawiski K, Nowicka Z, Burzyński J, Jędrzejczak N, Zięba A, Sławiński L, Peszyńska-Piorun M, Mouw KW, Masłowski M, Fendler W. Baseline lymphocyte count outperforms dosimetry and inflammatory markers for predicting severe radiation-induced lymphopenia in rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 2026. Published online 30 August 2026. doi:10.1016/j.ijrobp.2026.08.034 PMID 42669333First authorCorresponding authorKey research series
  3. Stawiski K, Kamran SC, Perera-Bel J, Lee J, Bellmunt J, Mouw KW, De Carvalho FLF. Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review. Briefings in Bioinformatics. 2026;27(5):bbag487. doi:10.1093/bib/bbag487 PMID 42721444First authorCorresponding authorKey research series
  4. Tomasik B, Jąkalski M, Bieńkowski M, Teodorczyk J, Sobocki BK, Stawiski K, Burzynski J, Romanowicz G, Dziadziuszko R, Cytawa W, Mieczkowski J. Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics. Journal of Translational Medicine. 2026;24(1):587. doi:10.1186/s12967-026-08029-w PMID 41851773
  5. Webber JW, Wollborn L, Mishra S, Alimena S, Testino B, Stawiski K, Fendler W, Chowdhury D, Elias KM. A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer. Scientific Reports. 2026;16(1):14813. doi:10.1038/s41598-026-45020-3 PMID 41876608
  6. Carvalho FLF, Lee J, Kalavros N, Zhou Y, Michaud D, Stelter I, Siddiqui H, Stawiski K, Ravindranathan R, Perera J, Wang S, Titchen B, Garza A, Bi K, Park J, Sterner EG, Egan JM, Hirohashi Y, Bekele RT, Epstein I, Vlachos I, Jia L, Kibel AS, Hirsch M, Bellmunt J, Guerriero JL, Mouw KW, Van Allen EM. Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer. Cell Press Blue. 2026;1(7):100100. doi:10.1016/j.cpblue.2026.100100 Preprint
  7. Kuna K, Burzyński J, Mikulski D, Sobocki B, Papis-Ubych A, Stawiski K, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Fendler W, Tomasik B. Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy. Współczesna Onkologia / Contemporary Oncology. 2026;30(1):33–39. doi:10.5114/wo.2025.158130 PMID 42089038
  8. Tomasik B, Mikulski D, Sobocki BK, Kuna K, Papis-Ubych A, Stawiski K, Burzyński J, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Fendler W. Circulating microRNAs as prognostic biomarkers in patients with oropharyngeal cancer undergoing radiotherapy: temporal dynamics analysis. Clinical and Experimental Medicine. 2026. Published online 18 July 2026. doi:10.1007/s10238-026-02237-w PMID 42471539

2025

  1. Golinska M, Rycerz A, Sobczak M, Chrzanowski J, Stawiski K, Fendler W. Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors – a network meta-analysis. Frontiers in Immunology. 2025;16:1619434. doi:10.3389/fimmu.2025.1619434 PMID 40698088Meta-analysis
  2. Pietrzak MM, Pietruszewska W, Barańska M, Rycerz A, Stawiski K, Niebudek-Bogusz E. Assessment of the Interdependencies Between High-Speed Videoendoscopy and Simultaneously Recorded Audio Data in Various Glottal Pathologies. Biomedicines. 2025;13(2):511. doi:10.3390/biomedicines13020511 PMID 40002924
  3. Kołowacik S, Bińkowski BJ, Stawiski K, Drożdż J. Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation. Polish Heart Journal. 2025;83(2):203–206. doi:10.33963/v.phj.103551 PMID 39743918

2024

  1. Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, Elias KM, Fendler W, Langseth H. Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches. Frontiers in Oncology. 2024;14:1389066. doi:10.3389/fonc.2024.1389066 PMID 38983926Equal first authorCorresponding authorKey research series
  2. Nowicka Z, Kuna K, Łaszczych M, Łazar-Poniatowska M, Sobocki BK, Stawiski K, Dąbrowski M, Bruski K, Zięba A, Pajdziński M, Staniewska E, Miszczyk M, Paganetti H, Fendler W, Tomasik B. Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques. Physics and Imaging in Radiation Oncology. 2024;30:100593. doi:10.1016/j.phro.2024.100593 PMID 38912008
  3. Brady P, Yousif A, Sasamoto N, Vitonis AF, Fendler W, Stawiski K, Hornstein MD, Terry KL, Elias KM, Missmer SA, Shafrir AL. Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use. Frontiers in Reproductive Health. 2024;6:1360417. doi:10.3389/frph.2024.1360417 PMID 38665804
  4. Puła A, Robak T, Dróżdż I, Stawiski K, Rycerz A, Misiewicz M, Robak P. Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study. Leukemia & Lymphoma. 2024;65(2):257–264. doi:10.1080/10428194.2023.2278431 PMID 37948578
  5. Nowicka Z, Kuna K, Stawiski K, Sołek J, Świderek M, Papis-Ubych A, Fijuth J, Fendler W, Tomasik B. Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes. Head & Neck. 2024;46(2):E10–E17. doi:10.1002/hed.27555 PMID 37867397Case report
  6. Mikulski D, Nowicki M, Dróżdż I, Perdas E, Strzałka P, Kościelny K, Misiewicz M, Stawiski K, Wierzbowska A, Fendler W. MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation. Biomarker Research. 2024;12(1):42. doi:10.1186/s40364-024-00585-x PMID 38650024
  7. Webber JW, Wollborn L, Mishra S, Vitonis AF, Cramer DW, Phan RT, Pappas TC, Stawiski K, Fendler W, Chowdhury D, Elias KM. Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass. Gynecologic Oncology. 2024;190:124–130. doi:10.1016/j.ygyno.2024.08.008 PMID 39180961
  8. Łochowska BA, Stawiski K, Kuna K, Nowicka Z, Łochowski M, Fijuth J. Predicting of overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab – a Polish real-world single-center experience. Nowotwory. Journal of Oncology. 2024. Polish version: Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory. 2024;9(3):190–196. doi:10.5603/njo.99179

2023

  1. Zhou Y, Börcsök J, Adib E, Kamran SC, Neil AJ, Stawiski K, Freeman D, Stormoen DR, Sztupinszki Z, Samant A, Nassar A, Bekele RT, Hanlon T, Valentine H, Epstein I, Sharma B, Felt K, Abbosh P, Wu CL, Efstathiou JA, Miyamoto DT, Anderson W, Szallasi Z, Mouw KW. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Science Advances. 2023;9(47):eadg2263. doi:10.1126/sciadv.adg2263 PMID 37992168
  2. Elias K, Smyczynska U, Stawiski K, Nowicka Z, Webber J, Kaplan J, Landen C, Lubinski J, Mukhopadhyay A, Chakraborty D, Connolly DC, Symecko H, Domchek SM, Garber JE, Konstantinopoulos P, Fendler W, Chowdhury D. Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles. Nature Communications. 2023;14(1):3350. doi:10.1038/s41467-023-38925-4 PMID 37291133
  3. Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, Ussowicz M, Chowdhury D, Fendler W. Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study. Radiotherapy and Oncology. 2023;185:109731. doi:10.1016/j.radonc.2023.109731 PMID 37301262
  4. Malinowski J, Pietruszewska W, Stawiski K, Pietrzak M, Barańska M, Rycerz A, Niebudek-Bogusz E. High-speed videoendoscopy enhances the objective assessment of glottic organic lesions: a case-control study with multivariable data-mining model development. Cancers. 2023;15(14):3716. doi:10.3390/cancers15143716 PMID 37509377
  5. Masłowski M, Stawiski K, Zięba A, Mikulski D, Bednarek J, Fijuth J. Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy – a pilot study. Nowotwory. Journal of Oncology. 2023;73(4):220–229. Polish version: Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory. 2023;8(4):274–283. doi:10.5603/njo.a2023.0032
  6. Miszczyk M, Magrowski Ł, Krzysztofiak T, Stando R, Majewski W, Stawiski K, Masri O, Ciepał J, Depowska G, Chimiak K, Bylica G, Czapla B, Masri M, Cichur F, Jabłońska I, Gmerek M, Nowicka Z, Wojcieszek P, Sadowski J, Suwiński R, Rajwa P, Goldner G, Moll M. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiotherapy and Oncology. 2023;183:109632. doi:10.1016/j.radonc.2023.109632 PMID 36963442

2022

  1. Mieczkowski K, Kitowska K, Braun M, Galikowska-Bogut B, Gorska-Arcisz M, Piasecka D, Stawiski K, Zaczek AJ, Nejc D, Kordek R, Romanska HM, Sadej R. FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. Molecular Oncology. 2022;16(15):2823–2842. doi:10.1002/1878-0261.13274 PMID 35726195
  2. Kuncman Ł, Orzechowska M, Stawiski K, Masłowski M, Ciążyńska M, Gottwald L, Milecki T, Fijuth J. The kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy suggests a potential gain from the earlier initiation of immunotherapy. Cancers. 2022;14(16):3844. doi:10.3390/cancers14163844 PMID 36010838
  3. Panek M, Stawiski K, Kaszkowiak M, Kuna P. Cytokine TGFbeta gene polymorphism in asthma: TGF-related SNP analysis enhances the prediction of disease diagnosis (a case-control study with multivariable data-mining model development). Frontiers in Immunology. 2022;13:746360. doi:10.3389/fimmu.2022.746360 PMID 35774789
  4. Fendler W, Tomasik B, Atkins K, Stawiski K, Chałubińska-Fendler J, Kozono D. The clinician’s guide to radiotherapy complications. Polish Archives of Internal Medicine. 2022;132(1):16190. doi:10.20452/pamw.16190 PMID 35089673Review
  5. Gockley A, Pagacz K, Fiascone S, Stawiski K, Holub N, Hasselblatt K, Cramer DW, Fendler W, Chowdhury D, Elias KM. A translational model to improve early detection of epithelial ovarian cancers. Frontiers in Oncology. 2022;12:786154. doi:10.3389/fonc.2022.786154 PMID 35530324
  6. Miszczyk M, Rembak-Szynkiewicz J, Magrowski Ł, Stawiski K, Namysł-Kaletka A, Napieralska A, Kraszkiewicz M, Woźniak G, Stąpór-Fudzińska M, Głowacki G, Pradere B, Laukhtina E, Rajwa P, Majewski W. The prognostic value of PI-RADS score in CyberKnife ultra-hypofractionated radiotherapy for localized prostate cancer. Cancers. 2022;14(7):1613. doi:10.3390/cancers14071613 PMID 35406385
  7. Bobeff EJ, Bukowiecka-Matusiak M, Stawiski K, Wiśniewski K, Burzynska-Pedziwiatr I, Kordzińska M, Kowalski K, Sendys P, Piotrowski M, Szczesna D, Stefańczyk L, Wozniak LA, Jaskólski DJ. Plasma amino acids may improve prediction accuracy of cerebral vasospasm after aneurysmal subarachnoid haemorrhage. Journal of Clinical Medicine. 2022;11(2):380. doi:10.3390/jcm11020380 PMID 35054073
  8. Kubik S, Jesionek-Kupnicka D, Stawiski K, Fijuth J, Moszynska-Zielinska M, Kuncman L, Pajdzinski M, Gottwald L. Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma. Journal of Obstetrics and Gynaecology. 2022;42(6):2248–2254. doi:10.1080/01443615.2022.2037124 PMID 35264072
  9. Bobeff EJ, Stawiski K, Stanisławska PA, Posmyk BJ, Wiśniewski K, Bryl M, Piotrowski MM, Fortuniak J, Jaskólski DJ. Validation of the elderly traumatic brain injury score: observational case control study. World Neurosurgery. 2022;161:e464–e472. doi:10.1016/j.wneu.2022.02.037 PMID 35176521
  10. Miszczyk M, Staniewska E, Jabłońska I, Lipka-Rajwa A, Stawiski K, Tarnawski R. Volumetric staging in radiotherapy for oropharyngeal cancers. Tumori Journal. 2022;108(6):586–591. doi:10.1177/03008916211050959 PMID 34628998
  11. Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Różański W, Soria F, Shariat SF, Fendler W. Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. European Urology Oncology. 2022;5(1):109–112. doi:10.1016/j.euo.2021.05.006 PMID 34092528Equal first authorCorresponding author

2021

  1. Robak P, Jarych D, Mikulski D, Dróżdż I, Węgłowska E, Kotkowska A, Misiewicz M, Smolewski P, Stawiski K, Fendler W, Szemraj J, Robak T. The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib. Cancers. 2021;13(5):951. doi:10.3390/cancers13050951 PMID 33668794
  2. Tomasik B, Papis-Ubych A, Stawiski K, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Fendler W. Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 2021;111(5):1237–1249. doi:10.1016/j.ijrobp.2021.07.008 PMID 34280472
  3. Panek M, Stawiski K, Kuna P. TGF-beta gene polymorphisms as risk factors for asthma control among clinic patients. Journal of Inflammation. 2021;18(1):28. doi:10.1186/s12950-021-00294-4 PMID 34620181
  4. Lee L, Howitt B, Cheng T, King M, Stawiski K, Fendler W, Chowdhury D, Matulonis U, Konstantinopoulos PA. MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. Gynecologic Oncology. 2021;163(3):453–458. doi:10.1016/j.ygyno.2021.09.015 PMID 34607711
  5. Miszczyk M, Majewski W, Stawiski K, Rasławski K, Rajwa P, Jabłońska I, Magrowski Ł, Masri O, Paradysz A, Miszczyk L. Prognostic factors in postoperative radiotherapy for prostate cancer – tertiary center experience. Radiology and Oncology. 2021;55(2):203–211. doi:10.2478/raon-2021-0017 PMID 33768769

2020

  1. Małachowska B, Tomasik B, Stawiski K, Kulkarni S, Guha C, Chowdhury D, Fendler W. Circulating microRNAs as biomarkers of radiation exposure: a systematic review and meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2020;106(2):390–402. doi:10.1016/j.ijrobp.2019.10.028 PMID 31655196Meta-analysis
  2. Jobczyk M, Stawiski K, Fendler W, Różański W. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis. Cancer Medicine. 2020;9(11):4014–4025. doi:10.1002/cam4.3007 PMID 32216043Equal first authorCorresponding author
  3. Robak P, Dróżdż I, Jarych D, Mikulski D, Węgłowska E, Siemieniuk-Ryś M, Misiewicz M, Stawiski K, Fendler W, Szemraj J, Smolewski P, Robak T. The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients. Cancers. 2020;12(9):2569. doi:10.3390/cancers12092569 PMID 32916955
  4. Kuncman Ł, Stawiski K, Masłowski M, Kucharz J, Fijuth J. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer. Strahlentherapie und Onkologie. 2020;196(11):998–1005. doi:10.1007/s00066-020-01659-z PMID 32621010
  5. Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, Kopczynski J, Nejc D, Kordek R, Sadej R, Romanska HM. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers. 2020;12(9):2713. doi:10.3390/cancers12092713 PMID 32971804

2019

  1. Nowicka Z, Stawiski K, Tomasik B, Fendler W. Extracellular miRNAs as biomarkers of head and neck cancer progression and metastasis. International Journal of Molecular Sciences. 2019;20(19):4799. doi:10.3390/ijms20194799 PMID 31569614Equal first authorReview
  2. Zmyslowska A, Waszczykowska A, Baranska D, Stawiski K, Borowiec M, Jurowski P, Fendler W, Mlynarski W. Optical coherence tomography and magnetic resonance imaging visual pathway evaluation in Wolfram syndrome. Developmental Medicine & Child Neurology. 2019;61(3):359–365. doi:10.1111/dmcn.14040 PMID 30246501
  3. Bobeff EJ, Fortuniak J, Bryszewski B, Wiśniewski K, Bryl M, Kwiecień K, Stawiski K, Jaskólski DJ. Mortality after traumatic brain injury in elderly patients: a new scoring system. World Neurosurgery. 2019;128:e129–e147. doi:10.1016/j.wneu.2019.04.060 PMID 30981800
  4. Kotlicka-Antczak M, Karbownik MS, Stawiski K, Pawełczyk A, Żurner N, Pawełczyk T, Strzelecki D, Fusar-Poli P. Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. European Psychiatry. 2019;58:72–79. doi:10.1016/j.eurpsy.2019.02.007 PMID 30870626
  5. Zakrzewska M, Gruszka R, Stawiski K, Fendler W, Kordacka J, Grajkowska W, Daszkiewicz P, Liberski PP, Zakrzewski K. Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors. BMC Cancer. 2019;19(1):544. doi:10.1186/s12885-019-5739-5 PMID 31170943
  6. Bobeff EJ, Posmyk BJ, Bobeff KŁ, Fortuniak J, Wiśniewski K, Stawiski K, Stefańczyk L, Jaskólski DJ. Predicting outcome and conservative treatment failure in patients with skull fracture after traumatic brain injury: a retrospective cohort study. Journal of Neurological Surgery Part A: Central European Neurosurgery. 2019;80(6):460–469. doi:10.1055/s-0039-1692672 PMID 31466104

2018

  1. Komseli ES, Pateras IS, Krejsgaard T, Stawiski K, Rizou SV, Polyzos A, Roumelioti FM, Chiourea M, Mourkioti I, Paparouna E, Zampetidis CP, Gumeni S, Trougakos IP, Pefani DE, O’Neill E, Gagos S, Eliopoulos AG, Fendler W, Chowdhury D, Bartek J, Gorgoulis VG. A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence. BMC Genomics. 2018;19(1):37. doi:10.1186/s12864-017-4375-1 PMID 29321003
  2. Pagacz K, Stawiski K, Szadkowska A, Mlynarski W, Fendler W. GlyCulator2: an update on a web application for calculation of glycemic variability indices. Acta Diabetologica. 2018;55(8):877–880. doi:10.1007/s00592-018-1140-0 PMID 29651558
  3. Puła A, Stawiski K, Braun M, Iskierka-Jażdżewska E, Robak T. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. Leukemia & Lymphoma. 2018;59(5):1084–1094. doi:10.1080/10428194.2017.1375101 PMID 28891366Equal first authorMeta-analysis
  4. Stawiski K, Pietrzak I, Młynarski W, Fendler W, Szadkowska A. NIRCa: An artificial neural network-based insulin resistance calculator. Pediatric Diabetes. 2018;19(2):231–235. doi:10.1111/pedi.12551 PMID 28626972First author

2017

  1. Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, Frendl G, Konstantinopoulos P, Crum CP, Kedzierska M, Cramer DW, Chowdhury D. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. eLife. 2017;6:e28932. doi:10.7554/eLife.28932 PMID 29087294
  2. Trelinska J, Dachowska I, Baranska D, Stawiski K, Kotulska K, Fendler W, Jozwiak S, Mlynarski W. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatric Blood & Cancer. 2017;64(6):e26347. doi:10.1002/pbc.26347 PMID 27860334
  3. Stawiski K, Trelińska J, Baranska D, Dachowska I, Kotulska K, Jóźwiak S, Fendler W, Młynarski W. What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods. Magnetic Resonance Materials in Physics, Biology and Medicine. 2017;30(4):397–405. doi:10.1007/s10334-017-0614-3 PMID 28321524First author

2015

  1. Dziki Ł, Puła A, Stawiski K, Mudza B, Włodarczyk M, Dziki A. Patients’ awareness of the prevention and treatment of colorectal cancer. Polish Journal of Surgery. 2015;87(9):459–463. doi:10.1515/pjs-2015-0088 PMID 26812841

Preprint

  • Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczyński A, et al. OmicSelector: automatic feature selection and deep learning modeling for omic experiments. bioRxiv. 2022. doi:10.1101/2022.06.01.494299First author

Peer-reviewed conference paper

  • Stawiski K, Strzałka A, Puła A, Bijakowski K. PancreApp: an innovative approach to computational individualization of nutritional therapy in chronic gastrointestinal disorders. In: MEDINFO 2015: eHealth-enabled Health. 2015:325–328. doi:10.3233/978-1-61499-564-7-325 PMID 26262064First author

Scientific correspondence and correction

  • Nowicka Z, Bibik R, Stando R, Fendler W, Stawiski K, Tomasik B. A link between seasonality and radiation-related toxicity: The big time or time will tell? Radiotherapy and Oncology. 2021;161:257–258. Scientific correspondence. doi:10.1016/j.radonc.2021.06.010 PMID 34119584
  • Komseli ES, Pateras IS, Krejsgaard T, Stawiski K, Rizou SV, Polyzos A, et al. Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence. BMC Genomics. 2021;22(1):327. Correction to the 2018 BMC Genomics article. doi:10.1186/s12864-021-07608-z PMID 33952190

Book chapters

  • Stawiski K, Polak Ł, Fendler W, Drożdż J. Evidence-based medicine w kardiologii. In: Wielka Interna. Kardiologia, część 1, wydanie II. Medical Tribune Polska; 2018.First author
  • Stawiski K, Fijuth J. Sztuczna inteligencja w onkologii. In: Innowacyjna Onkologia: potrzeby, możliwości, system. PZWL; 2020. ISBN 978-83-200-6032-4.First author

Conference abstracts (23)

Show all abstracts
  • Cichocki P, Stawiski K, Mikołajczak R, Wojdowska W, Garnuszek P, Adamczewski Z. Porównanie badań 99mTc-PSMA-T4 SPECT i 68Ga-PSMA PET. XIX Zjazd Naukowy Polskiego Towarzystwa Medycyny Nuklearnej „Medycyna Nuklearna 360° – Dokładna Diagnostyka – Precyzyjne Leczenie”. Polskie Towarzystwo Medycyny Nuklearnej; 2026.
  • Pajdziński M, Burzyński J, Zięba A, Jędrzejczak N, Fijuth J, Stawiski K. Risk of Neutropenia With or Without Daratumumab in Bortezomib-Based First-Line Chemotherapy and Radiotherapy for Multiple Myeloma: A Pilot Study. Radiotherapy and Oncology. 2025;206:S919–S920. Abstract 4474. doi:10.1016/s0167-8140(25)03401-2
  • Stawiski K, Rycerz A, Burzyński J, Kasper K, Fendler W. Radonek – fine-tuned GPT-4o for Radiation Oncology Patient Support: Preliminary Evaluation and Protocol for Prospective Validation. Radiotherapy and Oncology. 2025;206:S2417–S2418. Abstract 4567. doi:10.1016/s0167-8140(25)03461-9First author
  • Cichocki P, Stawiski K, Mikołajczak R, Wojdowska W, Garnuszek P, Adamczewski Z. Head-to-head comparison of 99mTc-PSMA-T4 SPECT and 68Ga-PSMA PET studies. EANM Innovation. 2025;1(Supplement):EP-0360.
  • Nowicka Z, Kuna K, Łaszczych M, Stawiski K, Tomasik B, Fendler W. Effect of the time-of-day of radiotherapy administration on radiation-induced lymphocyte depletion in lung cancer. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2):e52. doi:10.1016/j.ijrobp.2024.07.1892
  • Stawiski K, Bilski M, Nowak-Potemska J, Bilewicz M, Fijuth J. Radiation induced lymphopenia depends on lymph node irradiation in prostate cancer radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2):e549–e550. doi:10.1016/j.ijrobp.2024.07.1216First author
  • Masłowski M, Stawiski K, Zięba A, Mikulski D, Bednarek J, Fijuth J. Predicting neutropenia dynamics after RT in first-line Bortezomib-based chemo for MM – a pilot study. Radiotherapy and Oncology. 2024;194:S1165–S1168. Abstract 1994. doi:10.1016/s0167-8140(24)02292-8
  • Stawiski K, Pajdziński M, Zięba A, Masłowski M, Fijuth J. Development of a CT-only autosegmentation model for hippocampal delineation in radiation therapy. Radiotherapy and Oncology. 2024;194:S3165–S3166. Abstract 3178. doi:10.1016/s0167-8140(24)03230-4First author
  • Magnani CJ, D’Andrea VD, Stawiski K, Stelter I, Hanlon T, Jia L, et al. AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior. European Urology. 2024;85:S219–S220. doi:10.1016/s0302-2838(24)00235-5
  • De Carvalho FLF, Lee J, Bi K, Titchen B, Stawiski K, Park J, et al. Tumor-immune interactions and cisplatin resistance in localized muscle-invasive bladder cancer. Cancer Research. 2024;84(6_Supplement):7041. doi:10.1158/1538-7445.am2024-7041
  • Mohammed F, Stawiski K, Musa HS, Owolabi SK, Abubakar S, Rotimi SO, et al. Co-expression of HERV-R, CCND1, BRAF, FOXA1, TMPRSS2, ATF4 and low expression of BAZ1B and KMT2D is associated with early detection and poor prognosis of prostate cancer in African Black men from Nigeria. Cancer Research. 2024;84(6_Supplement):6432. doi:10.1158/1538-7445.am2024-6432
  • Stawiski K, Masłowski M, Masłowska W, Kordzińska M, Łochowska B, et al. Clinical and Radiomics-Based Deep Learning Predictive Model for Early Treatment Failure after Neoadjuvant Radiochemotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. 2022;114(3):e150. doi:10.1016/j.ijrobp.2022.07.1004First author
  • Napieralska A, Bochenek-Cibor J, Chyrek A, Konkol M, Pawłowska E, et al. Improving Education in Radiation Oncology in Poland. International Journal of Radiation Oncology, Biology, Physics. 2022;114(1):e4–e5. doi:10.1016/j.ijrobp.2022.06.004
  • Mikulski D, Nowicki M, Dróżdż I, Perdas E, Strzałka P, Kościelny K, et al. Serum miRNA-based neural network models for predicting complications in patients receiving high-dose melphalan or BeEAM conditioning chemotherapy. Acta Haematologica Polonica. 2022;53(Suplement A):P030.
  • Miszczyk M, Ciepał J, Stando R, Masri O, Jabłońska I, Stawiski K, et al. The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2022;114(3):e231. doi:10.1016/j.ijrobp.2022.07.1190
  • Mikulski D, Dróżdż I, Perdas E, Stawiski K, Nowicki M, Misiewicz M, et al. Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation. Blood. 2021;138:4789. doi:10.1182/blood-2021-152179
  • Nowicka Z, Tomasik B, Kozono DE, Stawiski K, Johnson TJ, et al. Serum Circulating MicroRNAs as Functional Biodosimeters in Patients Undergoing Total Body Irradiation. International Journal of Radiation Oncology, Biology, Physics. 2020;108(3):e536. doi:10.1016/j.ijrobp.2020.07.1672
  • Kuncman Ł, Stawiski K, Masłowski M, Wilczyńska J, Bury J, Fijuth J. FT3-L Dynamics in Blood Could be Predictive of Time of Occurrence Lymphocyte Nadir in Patients Undergoing Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):E167–E168. doi:10.1016/j.ijrobp.2019.06.2148
  • Jaskólski DJ, Bobeff EJ, Stawiski K. Brain injury in elderly patients: a new scoring system. WFNS 2019 International Meeting “One world, one neurosurgery”, Belgrade, 21–24 March 2019. Serbian Neurosurgical Society; 2019:305.
  • Puła A, Stawiski K, Braun M, Iskierka-Jażdżewska E, Robak T. Bezpieczeństwo i efektywność kliniczna nowych inhibitorów szlaku sygnałowego receptorów limfocytów B w leczeniu nawrotowej i opornej przewlekłej białaczki limfocytowej: przegląd systematyczny i metaanaliza. XXVII Zjazd Polskiego Towarzystwa Hematologów i Transfuzjologów (oral presentation). Acta Haematologica Polonica. 2017;48(Supl. 1):s126.
  • Zakrzewska M, Fendler W, Stawiski K, Gruszka R, Zakrzewski K, et al. Comparative Analysis of miRNA Expression in Pediatric Neuronal and Mixed Neuronal-Glial Tumors. Pediatric Blood & Cancer. 2017;64:S318.
  • Lee LJ, Howitt BE, Fendler W, Stawiski K, Bu P, Cho L, et al. miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC). Journal of Clinical Oncology. 2017;35(15_suppl):e17116. doi:10.1200/jco.2017.35.15_suppl.e17116
  • Elias KM, Fendler WF, Stawiski K, Vitonis A, Berkowitz RS, Cramer DW, et al. Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer. Reproductive Sciences. 2017;24:87A.

Google Scholar publication records

Titles and author lists appear as Google Scholar shows them, with its citation counts. The complete verified record is listed above.

Show all records (96)
  • B Tomasik, M Jąkalski, M Bieńkowski, J Teodorczyk, BK Sobocki, … Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics Journal of Translational Medicine 2026: 24 (1), 587 [citations: 3]
  • FLF Carvalho, J Lee, N Kalavros, Y Zhou, D Michaud, I Stelter, H Siddiqui, … Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer Cell Press Blue 2026: 1 (7) [citations: 3]
  • JW Webber, L Wollborn, S Mishra, S Alimena, B Testino, K Stawiski, … A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer Scientific Reports 2026: 16 (1), 14813 [citations: 0]
  • K Stawiski, L Kuncman, M Bilski, C Franzese, M Orzechowska, K Bułacz, … Association of Pre-Treatment Sacral Bone Marrow Morphology with Radiation-Induced Lymphopenia in Prostate Cancer International Journal of Radiation Oncology, Biology, Physics 2026: 126 (1), e635 [citations: 0]
  • K Stawiski, Z Nowicka, J Burzyński, N Jędrzejczak, A Zięba, … Baseline Lymphocyte Count Outperforms Dosimetry and Inflammatory Markers for Predicting Severe Radiation-Induced Lymphopenia in Rectal Cancer International Journal of Radiation Oncology, Biology, Physics 2026 [citations: 0]
  • B Tomasik, D Mikulski, BK Sobocki, K Kuna, A Papis-Ubych, K Stawiski, … Circulating microRNAs as prognostic biomarkers in patients with oropharyngeal cancer undergoing radiotherapy: temporal dynamics analysis Clinical and Experimental Medicine 2026 [citations: 0]
  • L Kuncman, K Stawiski, M Bilski, C Franzese, M Orzechowska, K Bułacz, … High-Throughput Dosimetric Profiling of Pelvic Organs at Risk and Lymphopenia in Prostate Radiotherapy International Journal of Radiation Oncology, Biology, Physics 2026: 126 (1), e595 [citations: 0]
  • K Stawiski, Ł Kuncman, M Jobczyk, M Bilski, C Franzese, M Orzechowska, … Pre-Treatment Sacral Bone Geometry Predicts Radiation-Induced Lymphopenia in Prostate Cancer Available at SSRN 2026: 6506353 [citations: 0]
  • W Majewski, M Bilski, W Kamzol, K Stawiski, G Majewski, K Konopa, … Renal Function Preservation after Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Multicenter Real-World Experience International Journal of Radiation Oncology, Biology, Physics 2026: 126 (1), e603 [citations: 0]
  • K Kuna, J Burzyński, D Mikulski, B Sobocki, A Papis-Ubych, K Stawiski, … Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy Contemporary Oncology/Współczesna Onkologia 2026: 30 (1), 33-39 [citations: 0]
  • K Stawiski, SC Kamran, J Perera-Bel, J Lee, J Bellmunt, KW Mouw, … Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review Briefings in Bioinformatics 2026: 27 (5), bbag487 [citations: 0]
  • K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere, J Lee, … Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma Molecular Oncology 2026: 20 (9), 2340-2355 [citations: 0]
  • M Golinska, A Rycerz, M Sobczak, J Chrzanowski, K Stawiski, W Fendler Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors-a network meta-analysis Frontiers in Immunology 2025: 16, 1619434 [citations: 14]
  • M Pajdziński, J Burzyński, A Zięba, N Jędrzejczak, J Fijuth, K Stawiski 4474 Risk of Neutropenia With or Without Daratumumab in Bortezomib-Based First-Line Chemotherapy and Radiotherapy for Multiple Myeloma: A Pilot Study Radiotherapy and Oncology 2025: 206, S919-S920 [citations: 0]
  • K Stawiski, A Rycerz, J Burzyński, K Kasper, W Fendler 4567 Radonek-Fine-Tuned GPT-4o for Radiation Oncology Patient Support: Preliminary Evaluation and Protocol for Prospective Validation Radiotherapy and Oncology 2025: 206, S2417-S2418 [citations: 0]
  • MM Pietrzak, W Pietruszewska, M Barańska, A Rycerz, K Stawiski, … Assessment of the Interdependencies Between High-Speed Videoendoscopy and Simultaneously Recorded Audio Data in Various Glottal Pathologies Biomedicines 2025: 13 (2), 511 [citations: 0]
  • D Chowdhury, KM Elias, W Fendler, K Stawiski Circulating microrna signatures for ovarian cancer US Patent 2025: 12,385,099 [citations: 0]
  • D Chowdhury, W Fendler, K Stawiski Circulating microrna signatures for pancreatic cancer US Patent App. 2025: 18/577,387 [citations: 0]
  • S Kołowacik, BJ Bińkowski, K Stawiski, J Drożdż Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation Polish Heart Journal (Kardiologia Polska) 2025: 83 (2), 203-206 [citations: 0]
  • K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere Rodero, J Lee, … Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma bioRxiv 2025: 2025.02.27.640395 [citations: 0]
  • Z Nowicka, K Kuna, M Łaszczych, M Łazar-Poniatowska, BK Sobocki, … Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques Physics and Imaging in Radiation Oncology 2024: 30, 100593 [citations: 14]
  • P Brady, A Yousif, N Sasamoto, AF Vitonis, W Fendler, K Stawiski, … Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use Frontiers in Reproductive Health 2024: 6, 1360417 [citations: 9]
  • K Stawiski, RT Fortner, L Pestarino, SU Umu, R Kaaks, TB Rounge, … Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches Frontiers in oncology 2024: 14, 1389066 [citations: 5]
  • A Puła, T Robak, I Dróżdż, K Stawiski, A Rycerz, M Misiewicz, P Robak Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens-pilot study Leukemia & Lymphoma 2024: 65 (2), 257-264 [citations: 4]
  • Z Nowicka, K Kuna, M Łaszczych, K Stawiski, B Tomasik, W Fendler Effect of the time-of-day of radiotherapy administration on radiation-induced lymphocyte depletion in lung cancer International Journal of Radiation Oncology, Biology, Physics 2024: 120 (2), e52 [citations: 3]
  • Z Nowicka, K Kuna, K Stawiski, J Sołek, M Świderek, A Papis-Ubych, … Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes Head & Neck 2024: 46 (2), E10-E17 [citations: 2]
  • JW Webber, L Wollborn, S Mishra, AF Vitonis, DW Cramer, RT Phan, … Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass Gynecologic oncology 2024: 190, 124-130 [citations: 2]
  • D Mikulski, M Nowicki, I Dróżdż, E Perdas, P Strzałka, K Kościelny, … MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation Biomarker Research 2024: 12 (1), 42 [citations: 1]
  • K Stawiski, M Bilski, J Nowak-Potemska, M Bilewicz, J Fijuth Radiation induced lymphopenia depends on lymph node irradiation in prostate cancer radiotherapy International Journal of Radiation Oncology, Biology, Physics 2024: 120 (2), e549-e550 [citations: 1]
  • M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth 1994: Predicting neutropenia dynamics after RT in first-line Bortezomib-based chemo for MM-a pilot study Radiotherapy and Oncology 2024: 194, S1165-S1168 [citations: 0]
  • K Stawiski, M Pajdziński, A Zięba, M Masłowski, J Fijuth 3178: Development of a CT-only autosegmentation model for hippocampal delineation in radiation therapy. Radiotherapy and Oncology 2024: 194, S3165-S3166 [citations: 0]
  • CJ Magnani, VD DAndrea, K Stawiski, I Stelter, T Hanlon, L Jia, AS Kibel, … AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior European Urology 2024: 85, S219-S220 [citations: 0]
  • F Mohammed, K Stawiski, HS Musa, SK Owolabi, S Abubakar, SO Rotimi, … Co-expression of HERV-R, CCND1, BRAF, FOXA1, TMPRSS2, ATF4 and low expression of BAZ1B and KMT2D is associated with early detection and poor prognosis of prostate cancer in … Cancer Research 2024: 84 (6_Supplement), 6432-6432 [citations: 0]
  • BA Łochowska, K Stawiski, K Kuna, Z Nowicka, M Łochowski, J Fijuth Predicting overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab-a Polish real-world single-center experience Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2024: 9 (3), 190-196 [citations: 0]
  • A Suleja, M Bilski, E Laukhtina, P Rajwa, K Stawiski, M Miszczyk Radioterapia stereotaktyczna (SBRT) w leczeniu pierwotnie zlokalizowanego raka nerkowokomórkowego (RCC)-przegląd systematyczny i metaanaliza Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY 2024: 9 (Suppl. 1) [citations: 0]
  • FLF De Carvalho, J Lee, K Bi, B Titchen, K Stawiski, J Park, A Garza, … Tumor-immune interactions and cisplatin resistance in localized muscle-invasive bladder cancer Cancer Research 2024: 84 (6_Supplement), 7041-7041 [citations: 0]
  • M Miszczyk, Ł Magrowski, T Krzysztofiak, R Stando, W Majewski, … Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group … Radiotherapy and Oncology 2023: 183, 109632 [citations: 32]
  • Y Zhou, J Börcsök, E Adib, SC Kamran, AJ Neil, K Stawiski, D Freeman, … ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer Science advances 2023: 9 (47), eadg2263 [citations: 29]
  • K Elias, U Smyczynska, K Stawiski, Z Nowicka, J Webber, J Kaplan, … Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles Nature communications 2023: 14 (1), 3350 [citations: 23]
  • Z Nowicka, B Tomasik, D Kozono, K Stawiski, T Johnson, D Haas-Kogan, … Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study Radiotherapy and Oncology 2023: 185, 109731 [citations: 19]
  • J Malinowski, W Pietruszewska, K Stawiski, MM Pietrzak, M Barańska, … High-speed videoendoscopy enhances the objective assessment of glottic organic lesions: a case-control study with multivariable data-mining model development Cancers 2023: 15 (14), 3716 [citations: 5]
  • M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy-a pilot study Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023: 8 (4), 274-283 [citations: 1]
  • K Stawiski, J Perera-Bel, A Rodriguez-Vida, NJ Rodero, KW Mouw, … Assessing tumor-infiltrating immune cells and outcomes with cisplatin-versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum … Journal of Clinical Oncology 2023: 41 (16_suppl), 4583-4583 [citations: 0]
  • M Jobczyk, K Stawiski, M Kaszkowiak, P Rajwa, W Różański, F Soria, … Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer European urology oncology 2022: 5 (1), 109-112 [citations: 41]
  • K Mieczkowski, K Kitowska, M Braun, B Galikowska-Bogut, … FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer Molecular Oncology 2022: 16 (15), 2823-2842 [citations: 23]
  • Ł Kuncman, M Orzechowska, K Stawiski, M Masłowski, M Ciążyńska, … The kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy suggests a potential gain from the earlier initiation of immunotherapy Cancers 2022: 14 (16), 3844 [citations: 18]
  • M Panek, K Stawiski, M Kaszkowiak, P Kuna Cytokine TGFbeta gene polymorphism in asthma: TGF-related SNP analysis enhances the prediction of disease diagnosis (a case-control study with multivariable data-mining model … Frontiers in immunology 2022: 13, 746360 [citations: 14]
  • K Stawiski, M Kaszkowiak, D Mikulski, P Hogendorf, A Durczyński, … OmicSelector: automatic feature selection and deep learning modeling for omic experiments BioRxiv 2022: 2022.06.01.494299 [citations: 11]
  • W Fendler, B Tomasik, K Atkins, K Stawiski, J Chałubińska-Fendler, … The clinician’s guide to radiotherapy complications Polskie Archiwum Medycyny Wewnętrznej 2022: 132 (1, art. ID 16190) [citations: 11]
  • A Gockley, K Pagacz, S Fiascone, K Stawiski, N Holub, K Hasselblatt, … A translational model to improve early detection of epithelial ovarian cancers Frontiers in Oncology 2022: 12, 786154 [citations: 8]
  • M Miszczyk, J Rembak-Szynkiewicz, Ł Magrowski, K Stawiski, … The prognostic value of PI-RADS score in CyberKnife ultra-hypofractionated radiotherapy for localized prostate cancer Cancers 2022: 14 (7), 1613 [citations: 8]
  • S Kubik, D Jesionek-Kupnicka, K Stawiski, J Fijuth, … Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma Journal of Obstetrics and Gynaecology 2022: 42 (6), 2248-2254 [citations: 6]
  • EJ Bobeff, M Bukowiecka-Matusiak, K Stawiski, K Wiśniewski, … Plasma amino acids may improve prediction accuracy of cerebral vasospasm after aneurysmal subarachnoid haemorrhage Journal of Clinical Medicine 2022: 11 (2), 380 [citations: 6]
  • EJ Bobeff, K Stawiski, PA Stanisławska, BJ Posmyk, K Wiśniewski, M Bryl, … Validation of the elderly traumatic brain injury score: observational case control study World neurosurgery 2022: 161, e464-e472 [citations: 5]
  • D Chowdhury, KM Elias, W Fendler, K Stawiski Circulating microRNA signatures for ovarian cancer US Patent 2022: 11,214,839 [citations: 3]
  • K Stawiski, M Maslowski, W Maslowska, M Kordzinska, B Lochowska, … Clinical and Radiomics-Based Deep Learning Predictive Model for Early Treatment Failure after Neoadjuvant Radiochemotherapy for Rectal Cancer International Journal of Radiation Oncology, Biology, Physics 2022: 114 (3), e150 [citations: 0]
  • A Napieralska, J Bochenek-Cibor, A Chyrek, M Konkol, E Pawłowska, … Improving Education in Radiation Oncology in Poland International Journal of Radiation Oncology, Biology, Physics 2022: 114 (1), e4-e5 [citations: 0]
  • D Mikulski, M Nowicki, I Dróźdż, E Perdas, P Strzałka, K Kościelny, … Serum miRNA-based neural network models for predicting complications in patients receiving high-dose melphalan or BeEAM conditioning chemotherapy. Acta Haematologica Polonica 2022: 53 (A), 66 [citations: 0]
  • M Miszczyk, J Ciepał, R Stando, O Masri, I Jabłońska, K Stawiski, … The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy International Journal of Radiation Oncology, Biology, Physics 2022: 114 (3), e231 [citations: 0]
  • M Miszczyk, E Staniewska, I Jabłońska, A Lipka-Rajwa, K Stawiski, … Volumetric staging in radiotherapy for oropharyngeal cancers Tumori Journal 2022: 108 (6), 586-591 [citations: 0]
  • P Robak, D Jarych, D Mikulski, I Dróżdż, E Węgłowska, A Kotkowska, … The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib Cancers 2021: 13 (5), 951 [citations: 23]
  • B Tomasik, A Papis-Ubych, K Stawiski, J Fijuth, P Kędzierawski, … Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy International journal of radiation oncology, biology, physics 2021: 111 (5), 1237-1249 [citations: 19]
  • M Panek, K Stawiski, P Kuna TGF-beta gene polimorphisms as risk factors for asthma control among clinic patients Journal of Inflammation 2021: 18 (1), 28 [citations: 14]
  • L Lee, B Howitt, T Cheng, M King, K Stawiski, W Fendler, D Chowdhury, … MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma Gynecologic oncology 2021: 163 (3), 453-458 [citations: 9]
  • D Mikulski, I Dróżdż, E Perdas, K Stawiski, M Nowicki, M Misiewicz, … Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation Blood 2021: 138, 4789 [citations: 5]
  • M Miszczyk, W Majewski, K Stawiski, K Rasławski, P Rajwa, I Jabłońska, … Prognostic factors in postoperative radiotherapy for prostate cancer-tertiary center experience Radiology and Oncology 2021: 55 (2), 203-211 [citations: 4]
  • Z Nowicka, R Bibik, R Stando, W Fendler, K Stawiski, B Tomasik A link between seasonality and radiation-related toxicity: The big time or time will tell? Radiotherapy and Oncology 2021: 161, 257-258 [citations: 2]
  • ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence BMC genomics 2021: 22 (1), 327-327 [citations: 1]
  • B Małachowska, B Tomasik, K Stawiski, S Kulkarni, C Guha, … Circulating microRNAs as biomarkers of radiation exposure: a systematic review and meta-analysis International Journal of Radiation Oncology, Biology, Physics 2020: 106 (2), 390-402 [citations: 73]
  • M Jobczyk, K Stawiski, W Fendler, W Różański Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC … Cancer medicine 2020: 9 (11), 4014-4025 [citations: 66]
  • Ł Kuncman, K Stawiski, M Masłowski, J Kucharz, J Fijuth Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer Strahlentherapie und Onkologie 2020: 196 (11), 998-1005 [citations: 30]
  • P Robak, I Dróżdż, D Jarych, D Mikulski, E Węgłowska, M Siemieniuk-Ryś, … The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients Cancers 2020: 12 (9), 2569 [citations: 28]
  • M Braun, D Piasecka, B Tomasik, K Mieczkowski, K Stawiski, A Zielinska, … Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma Cancers 2020: 12 (9), 2713 [citations: 18]
  • Z Nowicka, B Tomasik, DE Kozono, K Stawiski, TJ Johnson, … Serum Circulating MicroRNAs as Functional Biodosimeters in Patients Undergoing Total Body Irradiation International Journal of Radiation Oncology, Biology, Physics 2020: 108 (3), e536 [citations: 0]
  • Z Nowicka, K Stawiski, B Tomasik, W Fendler Extracellular miRNAs as biomarkers of head and neck cancer progression and metastasis International Journal of Molecular Sciences 2019: 20 (19), 4799 [citations: 47]
  • EJ Bobeff, J Fortuniak, B Bryszewski, K Wiśniewski, M Bryl, K Kwiecień, … Mortality after traumatic brain injury in elderly patients: a new scoring system World neurosurgery 2019: 128, e129-e147 [citations: 29]
  • A Zmyslowska, A Waszczykowska, D Baranska, K Stawiski, M Borowiec, … Optical coherence tomography and magnetic resonance imaging visual pathway evaluation in Wolfram syndrome Developmental Medicine & Child Neurology 2019: 61 (3), 359-365 [citations: 28]
  • M Kotlicka-Antczak, MS Karbownik, K Stawiski, A Pawełczyk, N Żurner, … Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state European Psychiatry 2019: 58, 72-79 [citations: 28]
  • M Zakrzewska, R Gruszka, K Stawiski, W Fendler, J Kordacka, … Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors BMC cancer 2019: 19 (1), 544 [citations: 19]
  • EJ Bobeff, BJ Posmyk, K Bobeff, J Fortuniak, K Wiśniewski, K Stawiski, … Predicting outcome and conservative treatment failure in patients with skull fracture after traumatic brain injury: a retrospective cohort study Journal of Neurological Surgery Part A: Central European Neurosurgery 2019: 80 (06 … [citations: 6]
  • L Kuncman, K Stawiski, M Maslowski, J Wilczynska, J Bury, J Fijuth FT3-L Dynamics in Blood Could be Predictive of Time of Occurrence Lymphocyte Nadir in Patients Undergoing Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics 2019: 105 (1), E167-E168 [citations: 0]
  • ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced … BMC genomics 2018: 19 (1), 37 [citations: 61]
  • K Pagacz, K Stawiski, A Szadkowska, W Mlynarski, W Fendler GlyCulator2: an update on a web application for calculation of glycemic variability indices Acta diabetologica 2018: 55 (8), 877-880 [citations: 38]
  • A Puła, K Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized … Leukemia & Lymphoma 2018: 59 (5), 1084-1094 [citations: 24]
  • K Stawiski, I Pietrzak, W Młynarski, W Fendler, A Szadkowska NIRCa: An artificial neural network-based insulin resistance calculator Pediatric Diabetes 2018: 19 (2), 231-235 [citations: 14]
  • KM Elias, W Fendler, K Stawiski, SJ Fiascone, AF Vitonis, RS Berkowitz, … Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer elife 2017: 6, e28932 [citations: 178]
  • J Trelinska, I Dachowska, D Baranska, K Stawiski, K Kotulska, W Fendler, … Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study) Pediatric blood & cancer 2017: 64 (6), e26347 [citations: 37]
  • K Stawiski, J Trelińska, D Baranska, I Dachowska, K Kotulska, S Jóźwiak, … What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods Magnetic Resonance Materials in Physics, Biology and Medicine 2017: 30 (4), 397-405 [citations: 9]
  • A Pula, K Stawiski, M Braun, E Iskierka-Jazdzewska, T Robak A systematic review and meta-analysis of B-cell receptor signaling inhibitors in relapsed and refractory chronic lymphocytic leukemia LEUKEMIA & LYMPHOMA 2017: 58, 152-153 [citations: 0]
  • A Puła, KG Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak Bezpieczeństwo i efektywność kliniczna nowych inhibitorów szlaku sygnałowego receptorów limfocytów B w leczeniu nawrotowej i opornej przewlekłej białaczki limfocytowej … Acta Haematologica Polonica 2017: 48 (Supl. 1) [citations: 0]
  • M Zakrzewska, W Fendler, K Stawiski, R Gruszka, K Zakrzewski, … Comparative Analysis of miRNA Expression in Pediatric Neuronal and Mixed Neuronal-Glial Tumors PEDIATRIC BLOOD & CANCER 2017: 64, S318-S318 [citations: 0]
  • LJ Lee, BE Howitt, W Fendler, K Stawiski, P Bu, L Cho, D Chowdhury, … miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC). Journal of Clinical Oncology 2017: 35 (15_suppl), e17116-e17116 [citations: 0]
  • KM Elias, WF Fendler, K Stawiski, A Vitonis, RS Berkowitz, DW Cramer, … Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer. REPRODUCTIVE SCIENCES 2017: 24, 87A-87A [citations: 0]
  • Ł Dziki, A Puła, K Stawiski, B Mudza, M Włodarczyk, A Dziki Patients’ awareness of the prevention and treatment of colorectal cancer Polish Journal of Surgery 2015: 87, 459-463 [citations: 15]
  • K Stawiski, A Strzałka, A Puła, K Bijakowski PancreApp: an innovative approach to computational individualization of nutritional therapy in chronic gastrointestinal disorders MEDINFO 2015: 2015: eHealth-enabled Health, 325-328 [citations: 10]
  • A Strzałka, K Stawiski, A Kaczmarek, A Kuchareczko, M Polguj, M Topol Analiza zmienności morfologicznych i topograficznych w zakresie struktur nerwowych i mięśniowych jamy pachowej (axillary fossa) w kontekście ich ewentualnych implikacji klinicznych Wydawnictwo Uniwersytetu Medycznego w Gdańsku 2013 [citations: 0]

Full publication records: PubMed, ORCID, OpenAlex, Google Scholar.

Teaching and invited lectures

Teaching and supervision

  • Medical University of Lodz: biostatistics, translational medicine, research methodology, evidence-based medicine, data mining and deep learning, with clinical examples in diagnostic tests, prognostic models and biomarkers.
  • Supervisor of the Student Scientific Group “Artificial Intelligence in Oncology”; student research supervision in Radonek-AI, including research questions, data organisation, response-quality assessment and scientific presentation.
  • 2024–2026: three editions of “Clinical Research – Design, Organisation and Implementation”, postgraduate programme at the Faculty of Pharmacy, Wrocław Medical University. Lectures and seminars: “Metodologia badania klinicznego”, “Wyniki badania klinicznego – analiza oraz ocena wartości”, “Karty Obserwacji Klinicznej (CRF)” and “Nowe technologie w badaniach klinicznych. Big Data”.
  • 2023: “Wyniki badania klinicznego - analiza oraz ocena wartości”, postgraduate studies “Non-commercial Clinical Research - Design, Implementation and Management”, Wrocław Medical University, Poland.
  • 2022: “Time series analysis”, postgraduate studies “Elements of empirical research methodology in medicine and application of statistics in biomedical research”, Medical University of Lodz, Poland.
  • 2022: “Introduction to Data Mining methods and the STATISTICA Data Miner system”, postgraduate studies “Elements of empirical research methodology in medicine and application of statistics in biomedical research”, Medical University of Lodz, Poland.
  • 2021–2022: “Data in clinical trials (CRF) and database management”, postgraduate studies “Non-commercial Clinical Research - Design, Implementation and Management”, Wrocław Medical University, Poland.
  • 2021–2022: “New Technologies in Clinical Trials. Big Data”, postgraduate studies “Non-commercial Clinical Research - Design, Implementation and Management”, Wrocław Medical University, Poland.

Invited lectures

  • 17 October 2026: “MDT w mHSPC – od wytycznych do optymalnego wyboru terapii”, 10th 4R – Radioterapeuci Radioterapeutom conference, session “Urologia – szybciej, dokładniej, mniej”, Warsaw, Poland.
  • 16 October 2026: “Rak odbytnicy: aktualna rola TNT, obszary napromieniania, a szczególnie zasady kontroli po leczeniu”, 10th 4R – Radioterapeuci Radioterapeutom conference, session “Organ preservation – radioterapia jako leczenie skuteczne i mało inwazyjne”, Warsaw, Poland.
  • 2025: “Jak sztuczna inteligencja może wpłynąć na zwiększenie możliwości realizacji radioterapii - praktyka i perspektywa?”, XI Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Lodz, Poland. Program
  • 2025: “Radioterapia w miejscowo zaawansowanym raku odbytnicy - należy eskalować leczenie systemowe”, Konferencja 4R “Dokąd zmierza nowoczesna radioterapia - Eskalacja czy Deeskalacja?”, Poland. Program
  • 2025: “Optymalizacja radio-chemioterapii po przezcewkowej resekcji (TMT) w raku pęcherza moczowego w świetle aktualnych badań”, “MISSION POSSIBLE” - Precyzja i personalizacja w onkologii, CMEducation, Warsaw, Poland. Program
  • 2025: “Leczenie trójmodalne vs cystektomia z leczeniem okołooperacyjnym - dla kogo co jest optymalnym wyborem?” - radiotherapist perspective, Uro-Onko Expert Meeting, CMEducation, Lodz, Poland. Program
  • 2024: “Total Neoadjuvant Treatment w raku odbytnicy - czy jest już standardem? Kiedy eskalować, kiedy deeskalować intensywność leczenia?”, VIII Konferencja 4R - Radioterapeuci Radioterapeutom, Warsaw, Poland. Program
  • 2024: “Synergia leczenia celowanego i radioterapii w badaniach klinicznych”, Precyzja i personalizacja - “MISSION POSSIBLE” w onkologii, CMEducation, Warsaw, Poland. Program
  • 2024: “Pisanie prac naukowych w dobie AI”, educational lecture/materials for Young PTRO. Slides
  • 2023: “Odmienne twarze Greja - dawki biologicznie równoważne w zależności od sposobu frakcjonowania i lokalizacji anatomicznej”, conference “Radioterapia stereotaktyczna w dobie leczenia celowanego”, Warsaw, Poland. Archived program
  • 2022: “Czy sztuczna inteligencja zastąpi człowieka w planowaniu leczenia promieniami?”, X Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Lodz, Poland.
  • 2022: “Deep artificial neural networks in the integration of the expression profile of circulating and intracellular miRNA molecules in pancreatic cancer patients”, Lodz Oncology Days, Lodz, Poland.
  • 2021: “Zastosowanie zaawansowanych narzędzi statystycznych i sztucznej inteligencji w prognozowaniu rokowania i odpowiedzi na leczenie w raku gruczołu krokowego”, “Rak stercza - wielodyscyplinarne podejście do terapii po niepowodzeniu leczenia miejscowego i w chorobie z przerzutami”, 90C webinar. Program
  • 2021: “Testy diagnostyczne, modele predykcyjne (regresja logistyczna)”, youngPTRO scientific-biostatistical workshops, Young Division of the Polish Society of Radiation Oncology. Recording
  • 2019: “Kobiety w nauce”, Pałacowy Salon Naukowy, Akademia Młodych Uczonych PAN, Jabłonna, Poland, with Beata Małachowska. Event page
  • 2019: “Nauczanie głębokie jako technika zwiększania skuteczności biomarkerów molekularnych”, IX Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Lodz, Poland. Archived program
  • 2018: “Data mining to discover ovarian cancer signature in the miRNA serum profile”, Elias Lab Meeting, Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Boston, MA, USA.
  • 2018: “From anatomy to artificial intelligence in oncology”, local science-outreach conference, Poland.

Research software, digital health projects and reproducible tools

Radiotherapy and clinical tools

  • rect-ril: R/Python analyses and an interactive calculator for severe lymphopenia during rectal cancer radiochemotherapy. Creator and maintainer. Public analysis code: Zenodo 10.5281/zenodo.19595347, version of 15 April 2026 (all versions), MIT licence; the internally validated model requires external validation.
  • RTpipeline: DICOM RT processing for dose-volume analysis, radiomics and prediction modelling. Creator and maintainer; Python, MIT licence. Documentation.
  • Prostate active-surveillance counselling calculators: biopsy-to-prostatectomy ISUP-grade upgrading risk (Jobczyk et al., 2026). Creator and maintainer of the public calculators.
  • deepNMIBC: recurrence and progression risk in non-muscle-invasive bladder cancer using recalibrated EORTC and CUETO models; released in June 2021. Python code.
  • GlyCulator2: web application for glycaemic-variability indices; co-author. Methods.
  • NIRCa: neural-network insulin-resistance calculator; first author of the model and tool. Methods.

Omics and biomarker software

  • Somatic Likelihood Tiering: documented evidence rules for prioritising tumour-only whole-exome variants for review. Creator and maintainer; Python, MIT licence. Version 2.1.0, Zenodo 10.5281/zenodo.21250820; all versions.
  • OmicSelector: R/Docker software for feature selection, biomarker signatures and deep-learning models, with nested cross-validation and feature-stability assessment; initially developed for miRNA-seq, RNA-seq and qPCR. Creator and maintainer; version 2.6.0, MIT licence. Documentation.
  • brca-classifier: circulating-microRNA model for identifying female BRCA1/2 variant carriers and data preparation. Creator and maintainer; R/Python. Model and data preparation; model archive licence CC BY 4.0.
  • miRNAselector: earlier miRNA-seq feature-selection and biomarker-signature software, superseded by OmicSelector. Creator and maintainer; R, MIT licence.
  • seq-pipeline: container environment for RNA-seq, small RNA-seq, exome and genome analysis, including RStudio, Jupyter Notebook, a code editor, file manager and OmicSelector. Creator and maintainer; Docker/PHP.
  • OmicApp: Shiny application framework integrating OmicSelector and omics modelling.
  • Evidence Bench: self-hosted research-analysis software with isolated Python/R execution, PubMed retrieval, deterministic result checks, independent review by a second model and recorded sources and processing steps; browser and Agent2Agent interfaces. Creator and maintainer; Apache 2.0 licence.

Digital health

  • Notatnik Medyczny: AI-assisted clinical documentation, including pre-visit intake, optical character recognition (OCR), dictation and quality checks.
  • Notatnik Medyczny (ADK Prototype): public hackathon prototype demonstrating selected AI-assisted medical-documentation functions.
  • Radioonkolog.pl: clinical profile, radiotherapy information for patients and clinicians, and analytical tools.
  • Radonek: oncology patient assistant based on a fine-tuned large language model, developed in Radonek-AI and made available through Radioonkolog.pl; project lead.
  • neurexam: interactive neurological examination assistant and electronic examination record.
  • PancreApp: individualised nutritional recommendations in chronic gastrointestinal disorders; project lead and first author of the conference paper.

Organizational activity

Editorial work and peer review

  • 2024–present: Editorial Board Member, BMC Cancer (Springer Nature).
  • ESTRO 2024 and ESTRO 2025 abstract reviewer.
  • 6 May 2025: co-chair, “Crossing the 2nd translational gap in radiation oncology: How do we ensure innovation gets to patients and delivers the best possible outcomes”, Interdisciplinary track, ESTRO 2025, Vienna (congress 2–6 May 2025).
  • 4 May 2024: co-chair, “Artificial intelligence in the daily clinic in a radiotherapy department”, Clinical track, ESTRO 2024, Glasgow (congress 3–7 May 2024).
  • Several dozen journal reviews, including World Journal of Urology, PLOS Genetics and Translational Andrology and Urology.
  • MEDINFO 2019 reviewer (17th World Congress on Medical and Health Informatics).

Memberships and service

  • 2023–2026: Full Member, appointed after application review for the 2023–2026 term, ESTRO AI in RT Focus Group, an international working group on artificial intelligence in radiation oncology.
  • 2021–present: Member of ESTRO (European Society for Radiotherapy and Oncology).
  • 2019–present: Member of the Polish Oncological Society.
  • 2019–present: Member of the Polish Society of Radiation Oncology.
  • 2017–2018: Member of the programme council, Kuźnia Młodych Talentów, Academy of Young Scholars of the Polish Academy of Sciences.
  • 2014–2016: Individual Course of Studies at the Department of Biostatistics and Translational Medicine; tutor: Dr Wojciech Fendler.
  • 2013–2015: President of the Student Scientific Society of the Medical University of Lodz.
  • 2012–2013: Member of the Board of the Student Scientific Society of the Medical University of Lodz.
  • 2012–2013: Individual Course of Studies at the Department of Neurosurgery and Oncology of the Nervous System; tutor: Dr Krzysztof Tybor.
  • 2012–2015: Member of the Student Scientific Society at the Department of Neurosurgery.
  • 2011–2015: Member of the Student Research Group at the Faculty of Normal and Clinical Anatomy.
  • 2011–2016: International Federation of Medical Students’ Associations (IFMSA): (1) 2014: European Regional Meeting of Medical Students, General Delegate of Poland, (2) 2013–2016: IFMSA New Technologies Support Division Director Assistant (international position), (3) 2013–2015: Member of the IFMSA-Poland marketing team (national position), (4) 2013–2015: IFMSA-Poland National New Technologies Director (national position), (5) 2012–2013: IFMSA-Poland National New Technologies Director Assistant (national position), (6) 2012–2013: Local coordinator of the project “Dying - a human thing” (local position), (7) 2011–2014: Local New Technologies Director (local position), (8) participation in 3 national IFMSA-Poland assemblies (Fall 2012, Spring 2012, Fall 2013).

Certified courses

  • 2025: Clinical Scholars Research Training programme, Harvard Medical School / Polish Medical Research Agency, advanced clinical research training, including Boston workshops on 17–20 November 2025.
  • 2022: Single-cell RNA-seq data analysis workshop, Harvard Chan Bioinformatics Core (HBC), Boston, MA, USA.
  • 2022: Bulk RNA-seq data analysis workshop (part 1 and 2), Harvard Chan Bioinformatics Core (HBC), Boston, MA, USA.
  • 2016: “Computational Genomics” (Summer School), Max-Delbrück-Centre for Molecular Medicine, Berlin, Germany.
  • 2016: “Fundamentals of Digital Image and Video Processing” (Coursera ID: ULTLWMZSCYEZ), Northwestern University, Evanston, IL, USA.

Skills

  • Clinical radiation oncology: genitourinary and gastrointestinal cancers; bladder-preserving trimodality therapy, prostate and rectal radiotherapy, SBRT/SRS, brachytherapy, radiochemotherapy, radioimmunotherapy, clinical trials, ward/team leadership, and multidisciplinary oncology care.
  • Translational oncology: radiomics, DICOM RT processing, dose-volume analytics, miRNA-seq, RNA-seq, single-cell RNA-seq, whole-exome sequencing, molecular biomarkers, radiation toxicity, and radiotherapy response modelling.
  • AI and biostatistics: prediction modelling, survival analysis, machine learning, deep learning, data mining, model validation, clinical decision tools, and reproducible analyses.
  • Research software and digital-health projects: R, R Markdown, Shiny, Python, Docker, sharing code through GitHub and Zenodo, web calculators, clinical documentation, OCR, dictation, quality checks, and secure web deployment.

Download this CV

The academic profile and full CV are available in English and Polish, as PDF and DOCX files.

Academic profileConcise scientific CV for review and collaboration.
English PDFEnglish DOCXPolish PDFPolish DOCX
Full academic CVComprehensive archive with the complete publication record and detailed service history.
English full PDFEnglish full DOCXPolish full PDFPolish full DOCX
Contact

This English CV was updated on 2026-11-07.

Jestem lekarzem specjalistą radioterapii onkologicznej, zajmującym się leczeniem szerokiego spektrum nowotworów, ze szczególnym uwzględnieniem nowotworów układu moczowo-płciowego i przewodu pokarmowego. W pracy naukowej badam biomarkery molekularne i kliniczne, toksyczność radioterapii oraz metody analizy danych w onkologii.

Profil akademicki Pełne CV

Portret Konrada Stawiskiego
Portret Konrada Stawiskiego
60artykułów w czasopismach
282,9sumaryczny Impact Factor
5 844punkty ministerialne
826cytowań w Scopus (782 w Web of Science)
16indeks Hirscha w Scopus i Web of Science
19indeks Hirscha w Google Scholar (1 169 cytowań)

Artykuły, Impact Factor, punkty, Scopus i Web of Science: Centrum Informacyjno-Biblioteczne Uniwersytetu Medycznego w Łodzi, stan na 13 października 2026 r.; Google Scholar: stan na 7 listopada 2026 r.

Podsumowanie

Konrad G. Stawiski jest lekarzem specjalistą radioterapii onkologicznej i zastępcą kierownika 34-łóżkowego Oddziału Brachyterapii i Onkologii Ogólnej w Szpitalu im. M. Kopernika w Łodzi. Jest adiunktem Uniwersytetu Medycznego w Łodzi oraz specjalistą ds. naukowych (post-doc) w projekcie STOPSTORM.eu w Narodowym Instytucie Onkologii, Oddziale w Gliwicach. W 2026 r. odbył finansowany pobyt badawczy jako Visiting Assistant Professor of Radiation Oncology w Dana-Farber Cancer Institute i Harvard Medical School.

W swoich badaniach wykazał, że większy udział limfocytów B pamięci w guzie wiąże się z dłuższym przeżyciem po chemioterapii opartej na platynie w zaawansowanym raku urotelialnym, głównie u chorych leczonych cisplatyną (HR 0,19; 95% CI 0,05–0,75). Podczas radiochemioterapii raka odbytnicy rutynowo oznaczana liczba limfocytów, wiek i płeć pozwalały przewidywać ciężką limfopenię, a dozymetria nie poprawiała tej oceny. Badał również sygnały krążących mikroRNA przed rozpoznaniem raka jajnika oraz opracował protokół ustalania kolejności przeglądu wariantów wykrytych w sekwencjonowaniu samego guza.

Google Scholar wykazuje 96 rekordów, w tym doniesienia zjazdowe, preprinty i patenty, z indeksem Hirscha 19 i liczbą cytowań 1 169. Jest współtwórcą dwóch rodzin patentowych dotyczących krążących mikroRNA, kieruje polską grupą i pakietem roboczym WP4 w ERA PerMed miRPOC, kierował zakończonymi projektami NCN PRELUDIUM i Radonek-AI oraz uczestniczy jako współbadacz (Sub-Investigator) w badaniach onkologicznych faz II–III. Rozwija oprogramowanie badawcze, sprawuje opiekę naukową nad studentami i jest członkiem Editorial Board BMC Cancer.

Doświadczenie zawodowe

  • Od 7 stycznia 2025 r.: Specjalista ds. naukowych (post-doc), STOPSTORM.eu, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach. Pakiet roboczy WP5: analiza rejestru i przygotowanie planu analizy; modelowanie predykcyjne wyników leczenia; modelowanie prawdopodobieństwa powikłań w tkankach zdrowych (NTCP) serca; automatyczna segmentacja struktur serca, szacowanie dawki i ocena biomarkerów radiomicznych.
  • 2024–obecnie: Adiunkt, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
    • Opiekun Studenckiego Koła Naukowego „Sztuczna Inteligencja w Onkologii”.
    • Zajęcia z biostatystyki, medycyny translacyjnej, metodologii badań, eksploracji danych, uczenia głębokiego i zastosowań AI.
    • Badania onkologiczne obejmujące bioinformatykę i analizę danych omicznych: radiomika, NGS, miRNA-seq, bulk/sc RNA-seq i WXS.
    • Lider polskiej grupy w międzynarodowym konsorcjum ERA PerMed miRPOC.
  • 2023–obecnie: Lekarz specjalista radioterapii onkologicznej, Zastępca Kierownika Oddziału Brachyterapii i Onkologii Ogólnej, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Łódź.
    • Zastępca lekarza kierującego 34-łóżkowym oddziałem, koordynujący radioterapię zewnętrzną, brachyterapię, jednoczasową radiochemioterapię i opiekę kliniczną w oddziale onkologii ogólnej.
  • 2021–2023: Asystent naukowo-dydaktyczny, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
  • 2018–2023: Lekarz rezydent radioterapii onkologicznej, Regionalny Ośrodek Onkologiczny, Szpital im. M. Kopernika w Łodzi.
    • Praca lekarska w Zakładzie Radioterapii oraz dyżury w Oddziale Radioterapii i Onkologii (referencje: prof. Jacek Fijuth).
    • Dodatkowe doświadczenie dyżurowe w Oddziale Hematoonkologii (referencje: prof. Piotr Smolewski).
  • 2017–2018: Specjalista bioinformatyki i informatyki medycznej, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
  • 2016–2017: Staż podyplomowy, Szpital MSWiA w Łodzi.

Zagraniczne pobyty badawcze

Były to pobyty badawcze finansowane przez Narodową Agencję Wymiany Akademickiej (NAWA), realizowane w Dana-Farber Cancer Institute w okresie zatrudnienia w Uniwersytecie Medycznym w Łodzi.

  • 1 lutego–31 lipca 2026 r.: Visiting Assistant Professor of Radiation Oncology, Dana-Farber Cancer Institute i Harvard Medical School, Boston, USA. Program im. prof. Franciszka Walczaka NAWA, BPN/WAL/2024/1/00014; opiekun: Kent W. Mouw. Projekt: „Integrated Multi-Modal Predictors of Response and Long-Term Survival in Muscle-Invasive Bladder Cancer Treated with Bladder-Sparing Trimodality Therapy” – zintegrowane wielomodalne predyktory odpowiedzi i długoterminowego przeżycia w raku pęcherza naciekającym mięśniówkę leczonym terapią trójmodalną oszczędzającą pęcherz. Komunikat uczelni.
  • 1 sierpnia 2022 r.–1 lutego 2023 r.: Research Fellow in Radiation Oncology, Dana-Farber Cancer Institute; współpraca w środowisku Harvard Medical School i Broad Institute of MIT and Harvard, Boston, USA. Program im. Mieczysława Bekkera NAWA, BPN/BEK/2021/1/00065; opiekun: Kent W. Mouw (Mouw Lab), we współpracy z zespołem Filipego L.F. Carvalho (Carvalho Lab). Projekt dotyczący wzajemnych oddziaływań ekspresji genów podczas radioterapii i jednoczasowej immunoterapii raka pęcherza moczowego naciekającego mięśniówkę.

Praktyka kliniczna

Szeroki zakres radioterapii ze szczególnym uwzględnieniem nowotworów układu moczowo-płciowego i przewodu pokarmowego, zwłaszcza raka prostaty, raka pęcherza moczowego i raka odbytnicy; także nowotwory ośrodkowego układu nerwowego, płuca, przełyku i nowotwory hematologiczne. Stosowane metody obejmują teleradioterapię, brachyterapię, stereotaktyczną radioterapię pozaczaszkową (SBRT), radiochirurgię stereotaktyczną (SRS), radiochemioterapię i radioimmunoterapię, w tym radioterapię raka prostaty, leczenie trójmodalne oszczędzające pęcherz i radiochemioterapię raka odbytnicy.

Wielodyscyplinarna opieka uroonkologiczna. Udział w wielospecjalistycznych konsyliach onkologicznych w ramach szybkiej ścieżki onkologicznej DiLO w Szpitalu im. M. Kopernika (Lung Cancer Unit), Szpitalu im. N. Barlickiego (Uniwersytecki Szpital Kliniczny nr 1) i Szpitalu im. WAM (Uniwersytecki Szpital Kliniczny nr 2) w Łodzi. Doświadczenie dyżurowe w hematoonkologii podczas rezydentury obejmuje opiekę nad chorymi na szpiczaka mnogiego, chłoniaki i białaczki. Informacje kliniczne.

Badania kliniczne

Współbadacz (Sub-Investigator) w komercyjnych i niekomercyjnych badaniach klinicznych w ośrodku im. M. Kopernika w Łodzi, w tym we wszystkich pięciu poniższych badaniach: prowadzenie leczenia według protokołu, ocena odpowiedzi i bezpieczeństwa oraz dokumentowanie przebiegu terapii.

Wykształcenie

Staże i pobyty naukowe

Badania

Główny cykl badawczy

Wiarygodna interpretacja biomarkerów molekularnych i klinicznych w onkologii. Cztery prace określają warunki, w których mierzony sygnał zachowuje wartość diagnostyczną, prognostyczną lub interpretacyjną.

Sygnały mikroRNA przed rozpoznaniem raka jajnika

Czy sygnatura krążących mikroRNA odróżnia próbki pobrane bliżej rozpoznania? W badaniu eksploracyjnym obejmującym 80 kobiet, u których później rozpoznano inwazyjnego nabłonkowego raka jajnika, model 14 miRNA rozróżniał próbki surowicy pobrane mniej niż dwa lata przed rozpoznaniem od pobranych od dwóch do siedmiu lat wcześniej (mediana pola pod krzywą ROC [AUC] w zbiorach testowych 0,771 wobec 0,587 dla losowych zestawów 14 miRNA). Porównanie dotyczyło wyłącznie kobiet, które później zachorowały, więc nie było testem wykrywania raka; wynik uzasadnia prospektywną ocenę z udziałem grupy kontrolnej kobiet bez nowotworu.

Wkład: równorzędny pierwszy autor i autor korespondencyjny; metodyka analiz, modele uczenia maszynowego i walidacja, analizy ekspresji względem czasu do rozpoznania oraz oprogramowanie. Frontiers in Oncology, 2024.

Limfocyty B pamięci a przeżycie w zaawansowanym raku urotelialnym

Czy skład komórek odpornościowych guza dostarcza informacji prognostycznej podczas chemioterapii opartej na platynie? U 189 chorych z trzech kohort leczonych w pierwszej linii wyłącznie chemioterapią opartą na platynie większy naciek limfocytarny wiązał się z dłuższym przeżyciem całkowitym (HR 0,34; 95% CI 0,16–0,72), najsilniej dla limfocytów B pamięci (HR 0,19; 95% CI 0,05–0,75), głównie u leczonych cisplatyną, natomiast naciek mieloidalny wiązał się z krótszym przeżyciem. Jest to zależność prognostyczna, nie dowód uzasadniający wybór leku; wynik wspiera badania limfocytów B i trzeciorzędowych struktur limfoidalnych jako biomarkerów prognostycznych.

Wkład: równorzędny pierwszy autor; koncepcja i projekt badania, bioinformatyka i statystyka wspólnie z Júlią Perera-Bel, interpretacja, wspólne przygotowanie manuskryptu i pozyskanie finansowania. Molecular Oncology, 2026.

Ryzyko limfopenii podczas radiochemioterapii raka odbytnicy

Czy rutynowa morfologia pozwala przewidywać ciężką limfopenię i czy dozymetria poprawia tę ocenę? W grupie 179 chorych ciężka limfopenia wystąpiła u 76 ze 173 ocenionych chorych (44%). Model obejmujący wyjściową liczbę limfocytów (oznaczoną do 60 dni przed rozpoczęciem radioterapii, a u części chorych do 7 dni po nim), wiek i płeć uzyskał skorygowany o optymizm indeks zgodności 0,746; dodanie wskaźników zapalnych lub dozymetrii nie poprawiło przewidywania. Ciężka limfopenia nie wiązała się z odpowiedzią guza, a pozornie korzystny związek z przeżyciem w analizie nadiru (HR 0,22; 95% CI 0,07–0,64) zanikał w analizie zależnej od czasu (HR 0,93; 95% CI 0,34–2,53). Potencjalnym zastosowaniem jest ukierunkowana opieka wspomagająca u chorych wysokiego ryzyka; zastosowanie w innym ośrodku wymaga walidacji zewnętrznej, w tym oceny przydatności klinicznej.

Wkład: pierwszy autor i autor korespondencyjny; koncepcja, metodyka, przygotowanie danych, statystyka, oprogramowanie, wizualizacja i manuskrypt. International Journal of Radiation Oncology, Biology, Physics, 2026.

Przejrzysty przegląd wariantów w sekwencjonowaniu samego guza

Czy jawne reguły oceny dowodów pozwalają ustalić kolejność przeglądu wariantów bez sparowanej próbki prawidłowej? W referencyjnym zestawie SEQC2 HCC1395 najwyższa kategoria Somatic Likelihood Tiering (SLT-A) obejmowała 78 prawdziwych wariantów somatycznych spośród 101 kandydatów (dodatnia wartość predykcyjna 77,2%; 95% CI 68,1–84,3%), a kategorie od SLT-A do SLT-C zachowały 352 z 455 wariantów referencyjnych (77,4%). SLT-A objęła 18,2% wariantów wykrytych w analizie sparowanej w kohorcie raka urotelialnego HdM-BLCA-1 i 49,1% w kohorcie gruczolakoraka płuca LUAD-TW (odzysk oceniano u 32 ze 113 chorych); wartości te wyrażają zgodność z analizą sparowaną z próbką prawidłową, nie trafność diagnostyczną. Przy małej bazie próbek prawidłowych z innej serii SLT-A i SLT-B łącznie objęły tylko 8,3% wariantów referencyjnych w linii COLO829 i 12,6% w NCI-H1770, dlatego przeniesienie protokołu wymaga bazy dopasowanej do procesu laboratoryjnego. Protokół dokumentuje przesłanki priorytetyzacji wariantów do przeglądu i nie zastępuje sekwencjonowania ze sparowaną próbką prawidłową.

Wkład: pierwszy autor i autor korespondencyjny; koncepcja, reguły, oprogramowanie, analizy porównawcze, interpretacja i manuskrypt. Briefings in Bioinformatics, 2026.

Współpraca naukowa

Granty, projekty finansowane i innowacje

Nagrody, wyróżnienia i stypendia

Patenty i komercjalizacje

Circulating microRNA signatures for ovarian cancer. Współtwórcy: Dipanjan Chowdhury, Kevin M. Elias, Wojciech Fendler i Konrad Stawiski. Uprawnieni: Uniwersytet Medyczny w Łodzi, The Brigham and Women’s Hospital, Inc. i Dana-Farber Cancer Institute, Inc.

Circulating microRNA signatures for pancreatic cancer. Współtwórcy: Dipanjan Chowdhury, Wojciech Fendler i Konrad Stawiski. Zgłaszający: Uniwersytet Medyczny w Łodzi i Dana-Farber Cancer Institute, Inc. Rodzina zgłoszeń patentowych; pierwszeństwo 9 lipca 2021 r. Zgłoszenie międzynarodowe PCT/US2022/036608 z 9 lipca 2022 r., opublikowane jako WO2023283476A2 12 stycznia 2023 r. Publikacje zgłoszeń krajowych i regionalnych: CA3223723A1, AU2022306397A1, US20250092460A1, EP4367257A2, JP2024527370A.

Komercjalizacja. Licencji na rodzinę dotyczącą raka jajnika udzielono Aspira Women’s Health Inc. 20 marca 2023 r. Sygnatura krążących mikroRNA stanowi składową testu OVAinform (wcześniej OvaMDx). Badania zlecone prowadzone od sierpnia 2022 r. dotyczą nieinwazyjnego testu wykrywającego endometriozę ENDOinform (wcześniej EndoMDx), opartego na krążących mikroRNA i białkach. Konrad Stawiski odpowiada za analizy statystyczne i modele klasyfikacyjne w zespole Uniwersytetu Medycznego w Łodzi, współpracującym z Dana-Farber Cancer Institute i Brigham and Women’s Hospital.

Publikacje

Bibliometria

Na 60 artykułów składają się: 54 prace oryginalne, 3 metaanalizy, 2 prace poglądowe i 1 opis przypadku. Pierwszy lub równorzędny pierwszy autor co najmniej 10 artykułów i autor korespondencyjny 5 artykułów.

Okres Artykuły Sumaryczny Impact Factor Punkty ministerialne
Po uzyskaniu stopnia doktora 38 193,517 4 150
Przed uzyskaniem stopnia doktora 22 89,383 1 694
Razem 60 282,900 5 844
Baza danych Cytowania Bez autocytowań Indeks Hirscha
Web of Science Core Collection 782 758 16
Scopus 826 801 16

Centrum Informacyjno-Biblioteczne Uniwersytetu Medycznego w Łodzi, stan na 13 października 2026 r. Impact Factor i punkty ministerialne z roku publikacji; dla prac z 2026 r. najnowszy dostępny Impact Factor (2025). Podział według daty publikacji w ostatecznej formie; stopień doktora nadano 26 października 2021 r.

Indeks Hirscha według Google Scholar: 19
(cytowania = 1 169; rekordy = 96)
Cytowania według roku i rekordy publikacji według roku na podstawie uporządkowanych danych Google Scholar.

Cytowania według roku i rekordy publikacji według roku na podstawie uporządkowanych danych Google Scholar.

Do formalnego przeglądu publikacji należy korzystać z rekordów PubMed, ORCID i OpenAlex.

Międzynarodowa sieć współpracy

OpenAlex wskazuje obecnie współautorów publikacji afiliowanych w 14 krajach poza Polską. Liczba wspólnych prac według kraju: USA (50), Wlk. Bryt. (7), Grecja (5), Austria (4).

Mapa świata przedstawiająca kraje afiliacji współautorów publikacji; Polska jest oznaczona jako kraj bazowy, a pozostałe kraje są cieniowane według liczby wspólnych prac.

Mapa przedstawia kraje afiliacji współautorów według OpenAlex Works; opisuje współpracę publikacyjną, nie formalne umowy między instytucjami.

Wybrane publikacje i wkład

Artykuły w czasopismach (60)

2026

  1. Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma. Molecular Oncology. 2026;20(9):2340–2355. doi:10.1002/1878-0261.70276 PMID 42226382 PreprintRównorzędny pierwszy autorGłówny cykl badawczy
  2. Stawiski K, Nowicka Z, Burzyński J, Jędrzejczak N, Zięba A, Sławiński L, Peszyńska-Piorun M, Mouw KW, Masłowski M, Fendler W. Baseline lymphocyte count outperforms dosimetry and inflammatory markers for predicting severe radiation-induced lymphopenia in rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 2026. Publikacja online 30 sierpnia 2026 r. doi:10.1016/j.ijrobp.2026.08.034 PMID 42669333Pierwszy autorAutor korespondencyjnyGłówny cykl badawczy
  3. Stawiski K, Kamran SC, Perera-Bel J, Lee J, Bellmunt J, Mouw KW, De Carvalho FLF. Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review. Briefings in Bioinformatics. 2026;27(5):bbag487. doi:10.1093/bib/bbag487 PMID 42721444Pierwszy autorAutor korespondencyjnyGłówny cykl badawczy
  4. Tomasik B, Jąkalski M, Bieńkowski M, Teodorczyk J, Sobocki BK, Stawiski K, Burzynski J, Romanowicz G, Dziadziuszko R, Cytawa W, Mieczkowski J. Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics. Journal of Translational Medicine. 2026;24(1):587. doi:10.1186/s12967-026-08029-w PMID 41851773
  5. Webber JW, Wollborn L, Mishra S, Alimena S, Testino B, Stawiski K, Fendler W, Chowdhury D, Elias KM. A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer. Scientific Reports. 2026;16(1):14813. doi:10.1038/s41598-026-45020-3 PMID 41876608
  6. Carvalho FLF, Lee J, Kalavros N, Zhou Y, Michaud D, Stelter I, Siddiqui H, Stawiski K, Ravindranathan R, Perera J, Wang S, Titchen B, Garza A, Bi K, Park J, Sterner EG, Egan JM, Hirohashi Y, Bekele RT, Epstein I, Vlachos I, Jia L, Kibel AS, Hirsch M, Bellmunt J, Guerriero JL, Mouw KW, Van Allen EM. Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer. Cell Press Blue. 2026;1(7):100100. doi:10.1016/j.cpblue.2026.100100 Preprint
  7. Kuna K, Burzyński J, Mikulski D, Sobocki B, Papis-Ubych A, Stawiski K, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Fendler W, Tomasik B. Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy. Współczesna Onkologia / Contemporary Oncology. 2026;30(1):33–39. doi:10.5114/wo.2025.158130 PMID 42089038
  8. Tomasik B, Mikulski D, Sobocki BK, Kuna K, Papis-Ubych A, Stawiski K, Burzyński J, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Fendler W. Circulating microRNAs as prognostic biomarkers in patients with oropharyngeal cancer undergoing radiotherapy: temporal dynamics analysis. Clinical and Experimental Medicine. 2026. Publikacja online 18 lipca 2026 r. doi:10.1007/s10238-026-02237-w PMID 42471539

2025

  1. Golinska M, Rycerz A, Sobczak M, Chrzanowski J, Stawiski K, Fendler W. Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors – a network meta-analysis. Frontiers in Immunology. 2025;16:1619434. doi:10.3389/fimmu.2025.1619434 PMID 40698088Metaanaliza
  2. Pietrzak MM, Pietruszewska W, Barańska M, Rycerz A, Stawiski K, Niebudek-Bogusz E. Assessment of the Interdependencies Between High-Speed Videoendoscopy and Simultaneously Recorded Audio Data in Various Glottal Pathologies. Biomedicines. 2025;13(2):511. doi:10.3390/biomedicines13020511 PMID 40002924
  3. Kołowacik S, Bińkowski BJ, Stawiski K, Drożdż J. Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation. Polish Heart Journal. 2025;83(2):203–206. doi:10.33963/v.phj.103551 PMID 39743918

2024

  1. Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, Elias KM, Fendler W, Langseth H. Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches. Frontiers in Oncology. 2024;14:1389066. doi:10.3389/fonc.2024.1389066 PMID 38983926Równorzędny pierwszy autorAutor korespondencyjnyGłówny cykl badawczy
  2. Nowicka Z, Kuna K, Łaszczych M, Łazar-Poniatowska M, Sobocki BK, Stawiski K, Dąbrowski M, Bruski K, Zięba A, Pajdziński M, Staniewska E, Miszczyk M, Paganetti H, Fendler W, Tomasik B. Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques. Physics and Imaging in Radiation Oncology. 2024;30:100593. doi:10.1016/j.phro.2024.100593 PMID 38912008
  3. Brady P, Yousif A, Sasamoto N, Vitonis AF, Fendler W, Stawiski K, Hornstein MD, Terry KL, Elias KM, Missmer SA, Shafrir AL. Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use. Frontiers in Reproductive Health. 2024;6:1360417. doi:10.3389/frph.2024.1360417 PMID 38665804
  4. Puła A, Robak T, Dróżdż I, Stawiski K, Rycerz A, Misiewicz M, Robak P. Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study. Leukemia & Lymphoma. 2024;65(2):257–264. doi:10.1080/10428194.2023.2278431 PMID 37948578
  5. Nowicka Z, Kuna K, Stawiski K, Sołek J, Świderek M, Papis-Ubych A, Fijuth J, Fendler W, Tomasik B. Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes. Head & Neck. 2024;46(2):E10–E17. doi:10.1002/hed.27555 PMID 37867397Opis przypadku
  6. Mikulski D, Nowicki M, Dróżdż I, Perdas E, Strzałka P, Kościelny K, Misiewicz M, Stawiski K, Wierzbowska A, Fendler W. MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation. Biomarker Research. 2024;12(1):42. doi:10.1186/s40364-024-00585-x PMID 38650024
  7. Webber JW, Wollborn L, Mishra S, Vitonis AF, Cramer DW, Phan RT, Pappas TC, Stawiski K, Fendler W, Chowdhury D, Elias KM. Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass. Gynecologic Oncology. 2024;190:124–130. doi:10.1016/j.ygyno.2024.08.008 PMID 39180961
  8. Łochowska BA, Stawiski K, Kuna K, Nowicka Z, Łochowski M, Fijuth J. Predicting of overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab – a Polish real-world single-center experience. Nowotwory. Journal of Oncology. 2024. Wersja polska: Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory. 2024;9(3):190–196. doi:10.5603/njo.99179

2023

  1. Zhou Y, Börcsök J, Adib E, Kamran SC, Neil AJ, Stawiski K, Freeman D, Stormoen DR, Sztupinszki Z, Samant A, Nassar A, Bekele RT, Hanlon T, Valentine H, Epstein I, Sharma B, Felt K, Abbosh P, Wu CL, Efstathiou JA, Miyamoto DT, Anderson W, Szallasi Z, Mouw KW. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Science Advances. 2023;9(47):eadg2263. doi:10.1126/sciadv.adg2263 PMID 37992168
  2. Elias K, Smyczynska U, Stawiski K, Nowicka Z, Webber J, Kaplan J, Landen C, Lubinski J, Mukhopadhyay A, Chakraborty D, Connolly DC, Symecko H, Domchek SM, Garber JE, Konstantinopoulos P, Fendler W, Chowdhury D. Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles. Nature Communications. 2023;14(1):3350. doi:10.1038/s41467-023-38925-4 PMID 37291133
  3. Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, Ussowicz M, Chowdhury D, Fendler W. Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study. Radiotherapy and Oncology. 2023;185:109731. doi:10.1016/j.radonc.2023.109731 PMID 37301262
  4. Malinowski J, Pietruszewska W, Stawiski K, Pietrzak M, Barańska M, Rycerz A, Niebudek-Bogusz E. High-speed videoendoscopy enhances the objective assessment of glottic organic lesions: a case-control study with multivariable data-mining model development. Cancers. 2023;15(14):3716. doi:10.3390/cancers15143716 PMID 37509377
  5. Masłowski M, Stawiski K, Zięba A, Mikulski D, Bednarek J, Fijuth J. Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy – a pilot study. Nowotwory. Journal of Oncology. 2023;73(4):220–229. Wersja polska: Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory. 2023;8(4):274–283. doi:10.5603/njo.a2023.0032
  6. Miszczyk M, Magrowski Ł, Krzysztofiak T, Stando R, Majewski W, Stawiski K, Masri O, Ciepał J, Depowska G, Chimiak K, Bylica G, Czapla B, Masri M, Cichur F, Jabłońska I, Gmerek M, Nowicka Z, Wojcieszek P, Sadowski J, Suwiński R, Rajwa P, Goldner G, Moll M. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiotherapy and Oncology. 2023;183:109632. doi:10.1016/j.radonc.2023.109632 PMID 36963442

2022

  1. Mieczkowski K, Kitowska K, Braun M, Galikowska-Bogut B, Gorska-Arcisz M, Piasecka D, Stawiski K, Zaczek AJ, Nejc D, Kordek R, Romanska HM, Sadej R. FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. Molecular Oncology. 2022;16(15):2823–2842. doi:10.1002/1878-0261.13274 PMID 35726195
  2. Kuncman Ł, Orzechowska M, Stawiski K, Masłowski M, Ciążyńska M, Gottwald L, Milecki T, Fijuth J. The kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy suggests a potential gain from the earlier initiation of immunotherapy. Cancers. 2022;14(16):3844. doi:10.3390/cancers14163844 PMID 36010838
  3. Panek M, Stawiski K, Kaszkowiak M, Kuna P. Cytokine TGFbeta gene polymorphism in asthma: TGF-related SNP analysis enhances the prediction of disease diagnosis (a case-control study with multivariable data-mining model development). Frontiers in Immunology. 2022;13:746360. doi:10.3389/fimmu.2022.746360 PMID 35774789
  4. Fendler W, Tomasik B, Atkins K, Stawiski K, Chałubińska-Fendler J, Kozono D. The clinician’s guide to radiotherapy complications. Polish Archives of Internal Medicine. 2022;132(1):16190. doi:10.20452/pamw.16190 PMID 35089673Praca poglądowa
  5. Gockley A, Pagacz K, Fiascone S, Stawiski K, Holub N, Hasselblatt K, Cramer DW, Fendler W, Chowdhury D, Elias KM. A translational model to improve early detection of epithelial ovarian cancers. Frontiers in Oncology. 2022;12:786154. doi:10.3389/fonc.2022.786154 PMID 35530324
  6. Miszczyk M, Rembak-Szynkiewicz J, Magrowski Ł, Stawiski K, Namysł-Kaletka A, Napieralska A, Kraszkiewicz M, Woźniak G, Stąpór-Fudzińska M, Głowacki G, Pradere B, Laukhtina E, Rajwa P, Majewski W. The prognostic value of PI-RADS score in CyberKnife ultra-hypofractionated radiotherapy for localized prostate cancer. Cancers. 2022;14(7):1613. doi:10.3390/cancers14071613 PMID 35406385
  7. Bobeff EJ, Bukowiecka-Matusiak M, Stawiski K, Wiśniewski K, Burzynska-Pedziwiatr I, Kordzińska M, Kowalski K, Sendys P, Piotrowski M, Szczesna D, Stefańczyk L, Wozniak LA, Jaskólski DJ. Plasma amino acids may improve prediction accuracy of cerebral vasospasm after aneurysmal subarachnoid haemorrhage. Journal of Clinical Medicine. 2022;11(2):380. doi:10.3390/jcm11020380 PMID 35054073
  8. Kubik S, Jesionek-Kupnicka D, Stawiski K, Fijuth J, Moszynska-Zielinska M, Kuncman L, Pajdzinski M, Gottwald L. Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma. Journal of Obstetrics and Gynaecology. 2022;42(6):2248–2254. doi:10.1080/01443615.2022.2037124 PMID 35264072
  9. Bobeff EJ, Stawiski K, Stanisławska PA, Posmyk BJ, Wiśniewski K, Bryl M, Piotrowski MM, Fortuniak J, Jaskólski DJ. Validation of the elderly traumatic brain injury score: observational case control study. World Neurosurgery. 2022;161:e464–e472. doi:10.1016/j.wneu.2022.02.037 PMID 35176521
  10. Miszczyk M, Staniewska E, Jabłońska I, Lipka-Rajwa A, Stawiski K, Tarnawski R. Volumetric staging in radiotherapy for oropharyngeal cancers. Tumori Journal. 2022;108(6):586–591. doi:10.1177/03008916211050959 PMID 34628998
  11. Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Różański W, Soria F, Shariat SF, Fendler W. Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. European Urology Oncology. 2022;5(1):109–112. doi:10.1016/j.euo.2021.05.006 PMID 34092528Równorzędny pierwszy autorAutor korespondencyjny

2021

  1. Robak P, Jarych D, Mikulski D, Dróżdż I, Węgłowska E, Kotkowska A, Misiewicz M, Smolewski P, Stawiski K, Fendler W, Szemraj J, Robak T. The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib. Cancers. 2021;13(5):951. doi:10.3390/cancers13050951 PMID 33668794
  2. Tomasik B, Papis-Ubych A, Stawiski K, Fijuth J, Kędzierawski P, Sadowski J, Stando R, Bibik R, Graczyk Ł, Latusek T, Rutkowski T, Fendler W. Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 2021;111(5):1237–1249. doi:10.1016/j.ijrobp.2021.07.008 PMID 34280472
  3. Panek M, Stawiski K, Kuna P. TGF-beta gene polymorphisms as risk factors for asthma control among clinic patients. Journal of Inflammation. 2021;18(1):28. doi:10.1186/s12950-021-00294-4 PMID 34620181
  4. Lee L, Howitt B, Cheng T, King M, Stawiski K, Fendler W, Chowdhury D, Matulonis U, Konstantinopoulos PA. MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. Gynecologic Oncology. 2021;163(3):453–458. doi:10.1016/j.ygyno.2021.09.015 PMID 34607711
  5. Miszczyk M, Majewski W, Stawiski K, Rasławski K, Rajwa P, Jabłońska I, Magrowski Ł, Masri O, Paradysz A, Miszczyk L. Prognostic factors in postoperative radiotherapy for prostate cancer – tertiary center experience. Radiology and Oncology. 2021;55(2):203–211. doi:10.2478/raon-2021-0017 PMID 33768769

2020

  1. Małachowska B, Tomasik B, Stawiski K, Kulkarni S, Guha C, Chowdhury D, Fendler W. Circulating microRNAs as biomarkers of radiation exposure: a systematic review and meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2020;106(2):390–402. doi:10.1016/j.ijrobp.2019.10.028 PMID 31655196Metaanaliza
  2. Jobczyk M, Stawiski K, Fendler W, Różański W. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis. Cancer Medicine. 2020;9(11):4014–4025. doi:10.1002/cam4.3007 PMID 32216043Równorzędny pierwszy autorAutor korespondencyjny
  3. Robak P, Dróżdż I, Jarych D, Mikulski D, Węgłowska E, Siemieniuk-Ryś M, Misiewicz M, Stawiski K, Fendler W, Szemraj J, Smolewski P, Robak T. The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients. Cancers. 2020;12(9):2569. doi:10.3390/cancers12092569 PMID 32916955
  4. Kuncman Ł, Stawiski K, Masłowski M, Kucharz J, Fijuth J. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer. Strahlentherapie und Onkologie. 2020;196(11):998–1005. doi:10.1007/s00066-020-01659-z PMID 32621010
  5. Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, Kopczynski J, Nejc D, Kordek R, Sadej R, Romanska HM. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers. 2020;12(9):2713. doi:10.3390/cancers12092713 PMID 32971804

2019

  1. Nowicka Z, Stawiski K, Tomasik B, Fendler W. Extracellular miRNAs as biomarkers of head and neck cancer progression and metastasis. International Journal of Molecular Sciences. 2019;20(19):4799. doi:10.3390/ijms20194799 PMID 31569614Równorzędny pierwszy autorPraca poglądowa
  2. Zmyslowska A, Waszczykowska A, Baranska D, Stawiski K, Borowiec M, Jurowski P, Fendler W, Mlynarski W. Optical coherence tomography and magnetic resonance imaging visual pathway evaluation in Wolfram syndrome. Developmental Medicine & Child Neurology. 2019;61(3):359–365. doi:10.1111/dmcn.14040 PMID 30246501
  3. Bobeff EJ, Fortuniak J, Bryszewski B, Wiśniewski K, Bryl M, Kwiecień K, Stawiski K, Jaskólski DJ. Mortality after traumatic brain injury in elderly patients: a new scoring system. World Neurosurgery. 2019;128:e129–e147. doi:10.1016/j.wneu.2019.04.060 PMID 30981800
  4. Kotlicka-Antczak M, Karbownik MS, Stawiski K, Pawełczyk A, Żurner N, Pawełczyk T, Strzelecki D, Fusar-Poli P. Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. European Psychiatry. 2019;58:72–79. doi:10.1016/j.eurpsy.2019.02.007 PMID 30870626
  5. Zakrzewska M, Gruszka R, Stawiski K, Fendler W, Kordacka J, Grajkowska W, Daszkiewicz P, Liberski PP, Zakrzewski K. Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors. BMC Cancer. 2019;19(1):544. doi:10.1186/s12885-019-5739-5 PMID 31170943
  6. Bobeff EJ, Posmyk BJ, Bobeff KŁ, Fortuniak J, Wiśniewski K, Stawiski K, Stefańczyk L, Jaskólski DJ. Predicting outcome and conservative treatment failure in patients with skull fracture after traumatic brain injury: a retrospective cohort study. Journal of Neurological Surgery Part A: Central European Neurosurgery. 2019;80(6):460–469. doi:10.1055/s-0039-1692672 PMID 31466104

2018

  1. Komseli ES, Pateras IS, Krejsgaard T, Stawiski K, Rizou SV, Polyzos A, Roumelioti FM, Chiourea M, Mourkioti I, Paparouna E, Zampetidis CP, Gumeni S, Trougakos IP, Pefani DE, O’Neill E, Gagos S, Eliopoulos AG, Fendler W, Chowdhury D, Bartek J, Gorgoulis VG. A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence. BMC Genomics. 2018;19(1):37. doi:10.1186/s12864-017-4375-1 PMID 29321003
  2. Pagacz K, Stawiski K, Szadkowska A, Mlynarski W, Fendler W. GlyCulator2: an update on a web application for calculation of glycemic variability indices. Acta Diabetologica. 2018;55(8):877–880. doi:10.1007/s00592-018-1140-0 PMID 29651558
  3. Puła A, Stawiski K, Braun M, Iskierka-Jażdżewska E, Robak T. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. Leukemia & Lymphoma. 2018;59(5):1084–1094. doi:10.1080/10428194.2017.1375101 PMID 28891366Równorzędny pierwszy autorMetaanaliza
  4. Stawiski K, Pietrzak I, Młynarski W, Fendler W, Szadkowska A. NIRCa: An artificial neural network-based insulin resistance calculator. Pediatric Diabetes. 2018;19(2):231–235. doi:10.1111/pedi.12551 PMID 28626972Pierwszy autor

2017

  1. Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, Frendl G, Konstantinopoulos P, Crum CP, Kedzierska M, Cramer DW, Chowdhury D. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. eLife. 2017;6:e28932. doi:10.7554/eLife.28932 PMID 29087294
  2. Trelinska J, Dachowska I, Baranska D, Stawiski K, Kotulska K, Fendler W, Jozwiak S, Mlynarski W. Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study). Pediatric Blood & Cancer. 2017;64(6):e26347. doi:10.1002/pbc.26347 PMID 27860334
  3. Stawiski K, Trelińska J, Baranska D, Dachowska I, Kotulska K, Jóźwiak S, Fendler W, Młynarski W. What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods. Magnetic Resonance Materials in Physics, Biology and Medicine. 2017;30(4):397–405. doi:10.1007/s10334-017-0614-3 PMID 28321524Pierwszy autor

2015

  1. Dziki Ł, Puła A, Stawiski K, Mudza B, Włodarczyk M, Dziki A. Patients’ awareness of the prevention and treatment of colorectal cancer. Polish Journal of Surgery. 2015;87(9):459–463. doi:10.1515/pjs-2015-0088 PMID 26812841

Preprint

  • Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczyński A, i wsp. OmicSelector: automatic feature selection and deep learning modeling for omic experiments. bioRxiv. 2022. doi:10.1101/2022.06.01.494299Pierwszy autor

Praca w recenzowanych materiałach konferencyjnych

  • Stawiski K, Strzałka A, Puła A, Bijakowski K. PancreApp: an innovative approach to computational individualization of nutritional therapy in chronic gastrointestinal disorders. W: MEDINFO 2015: eHealth-enabled Health. 2015:325–328. doi:10.3233/978-1-61499-564-7-325 PMID 26262064Pierwszy autor

Korespondencja naukowa i korekta

  • Nowicka Z, Bibik R, Stando R, Fendler W, Stawiski K, Tomasik B. A link between seasonality and radiation-related toxicity: The big time or time will tell? Radiotherapy and Oncology. 2021;161:257–258. Korespondencja naukowa. doi:10.1016/j.radonc.2021.06.010 PMID 34119584
  • Komseli ES, Pateras IS, Krejsgaard T, Stawiski K, Rizou SV, Polyzos A, i wsp. Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence. BMC Genomics. 2021;22(1):327. Korekta artykułu z BMC Genomics z 2018 r. doi:10.1186/s12864-021-07608-z PMID 33952190

Rozdziały w książkach

  • Stawiski K, Polak Ł, Fendler W, Drożdż J. Evidence-based medicine w kardiologii. W: Wielka Interna. Kardiologia, część 1, wydanie II. Medical Tribune Polska; 2018.Pierwszy autor
  • Stawiski K, Fijuth J. Sztuczna inteligencja w onkologii. W: Innowacyjna Onkologia: potrzeby, możliwości, system. PZWL; 2020. ISBN 978-83-200-6032-4.Pierwszy autor

Doniesienia zjazdowe (23)

Pokaż wszystkie doniesienia
  • Cichocki P, Stawiski K, Mikołajczak R, Wojdowska W, Garnuszek P, Adamczewski Z. Porównanie badań 99mTc-PSMA-T4 SPECT i 68Ga-PSMA PET. XIX Zjazd Naukowy Polskiego Towarzystwa Medycyny Nuklearnej „Medycyna Nuklearna 360° – Dokładna Diagnostyka – Precyzyjne Leczenie”. Polskie Towarzystwo Medycyny Nuklearnej; 2026.
  • Pajdziński M, Burzyński J, Zięba A, Jędrzejczak N, Fijuth J, Stawiski K. Risk of Neutropenia With or Without Daratumumab in Bortezomib-Based First-Line Chemotherapy and Radiotherapy for Multiple Myeloma: A Pilot Study. Radiotherapy and Oncology. 2025;206:S919–S920. Abstrakt 4474. doi:10.1016/s0167-8140(25)03401-2
  • Stawiski K, Rycerz A, Burzyński J, Kasper K, Fendler W. Radonek – fine-tuned GPT-4o for Radiation Oncology Patient Support: Preliminary Evaluation and Protocol for Prospective Validation. Radiotherapy and Oncology. 2025;206:S2417–S2418. Abstrakt 4567. doi:10.1016/s0167-8140(25)03461-9Pierwszy autor
  • Cichocki P, Stawiski K, Mikołajczak R, Wojdowska W, Garnuszek P, Adamczewski Z. Head-to-head comparison of 99mTc-PSMA-T4 SPECT and 68Ga-PSMA PET studies. EANM Innovation. 2025;1(Supplement):EP-0360.
  • Nowicka Z, Kuna K, Łaszczych M, Stawiski K, Tomasik B, Fendler W. Effect of the time-of-day of radiotherapy administration on radiation-induced lymphocyte depletion in lung cancer. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2):e52. doi:10.1016/j.ijrobp.2024.07.1892
  • Stawiski K, Bilski M, Nowak-Potemska J, Bilewicz M, Fijuth J. Radiation induced lymphopenia depends on lymph node irradiation in prostate cancer radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2024;120(2):e549–e550. doi:10.1016/j.ijrobp.2024.07.1216Pierwszy autor
  • Masłowski M, Stawiski K, Zięba A, Mikulski D, Bednarek J, Fijuth J. Predicting neutropenia dynamics after RT in first-line Bortezomib-based chemo for MM – a pilot study. Radiotherapy and Oncology. 2024;194:S1165–S1168. Abstrakt 1994. doi:10.1016/s0167-8140(24)02292-8
  • Stawiski K, Pajdziński M, Zięba A, Masłowski M, Fijuth J. Development of a CT-only autosegmentation model for hippocampal delineation in radiation therapy. Radiotherapy and Oncology. 2024;194:S3165–S3166. Abstrakt 3178. doi:10.1016/s0167-8140(24)03230-4Pierwszy autor
  • Magnani CJ, D’Andrea VD, Stawiski K, Stelter I, Hanlon T, Jia L, i wsp. AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior. European Urology. 2024;85:S219–S220. doi:10.1016/s0302-2838(24)00235-5
  • De Carvalho FLF, Lee J, Bi K, Titchen B, Stawiski K, Park J, i wsp. Tumor-immune interactions and cisplatin resistance in localized muscle-invasive bladder cancer. Cancer Research. 2024;84(6_Supplement):7041. doi:10.1158/1538-7445.am2024-7041
  • Mohammed F, Stawiski K, Musa HS, Owolabi SK, Abubakar S, Rotimi SO, i wsp. Co-expression of HERV-R, CCND1, BRAF, FOXA1, TMPRSS2, ATF4 and low expression of BAZ1B and KMT2D is associated with early detection and poor prognosis of prostate cancer in African Black men from Nigeria. Cancer Research. 2024;84(6_Supplement):6432. doi:10.1158/1538-7445.am2024-6432
  • Stawiski K, Masłowski M, Masłowska W, Kordzińska M, Łochowska B, i wsp. Clinical and Radiomics-Based Deep Learning Predictive Model for Early Treatment Failure after Neoadjuvant Radiochemotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. 2022;114(3):e150. doi:10.1016/j.ijrobp.2022.07.1004Pierwszy autor
  • Napieralska A, Bochenek-Cibor J, Chyrek A, Konkol M, Pawłowska E, i wsp. Improving Education in Radiation Oncology in Poland. International Journal of Radiation Oncology, Biology, Physics. 2022;114(1):e4–e5. doi:10.1016/j.ijrobp.2022.06.004
  • Mikulski D, Nowicki M, Dróżdż I, Perdas E, Strzałka P, Kościelny K, i wsp. Serum miRNA-based neural network models for predicting complications in patients receiving high-dose melphalan or BeEAM conditioning chemotherapy. Acta Haematologica Polonica. 2022;53(Suplement A):P030.
  • Miszczyk M, Ciepał J, Stando R, Masri O, Jabłońska I, Stawiski K, i wsp. The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2022;114(3):e231. doi:10.1016/j.ijrobp.2022.07.1190
  • Mikulski D, Dróżdż I, Perdas E, Stawiski K, Nowicki M, Misiewicz M, i wsp. Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation. Blood. 2021;138:4789. doi:10.1182/blood-2021-152179
  • Nowicka Z, Tomasik B, Kozono DE, Stawiski K, Johnson TJ, i wsp. Serum Circulating MicroRNAs as Functional Biodosimeters in Patients Undergoing Total Body Irradiation. International Journal of Radiation Oncology, Biology, Physics. 2020;108(3):e536. doi:10.1016/j.ijrobp.2020.07.1672
  • Kuncman Ł, Stawiski K, Masłowski M, Wilczyńska J, Bury J, Fijuth J. FT3-L Dynamics in Blood Could be Predictive of Time of Occurrence Lymphocyte Nadir in Patients Undergoing Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):E167–E168. doi:10.1016/j.ijrobp.2019.06.2148
  • Jaskólski DJ, Bobeff EJ, Stawiski K. Brain injury in elderly patients: a new scoring system. WFNS 2019 International Meeting „One world, one neurosurgery”, Belgrad, 21–24 marca 2019 r. Serbian Neurosurgical Society; 2019:305.
  • Puła A, Stawiski K, Braun M, Iskierka-Jażdżewska E, Robak T. Bezpieczeństwo i efektywność kliniczna nowych inhibitorów szlaku sygnałowego receptorów limfocytów B w leczeniu nawrotowej i opornej przewlekłej białaczki limfocytowej: przegląd systematyczny i metaanaliza. XXVII Zjazd Polskiego Towarzystwa Hematologów i Transfuzjologów (doniesienie ustne). Acta Haematologica Polonica. 2017;48(Supl. 1):s126.
  • Zakrzewska M, Fendler W, Stawiski K, Gruszka R, Zakrzewski K, i wsp. Comparative Analysis of miRNA Expression in Pediatric Neuronal and Mixed Neuronal-Glial Tumors. Pediatric Blood & Cancer. 2017;64:S318.
  • Lee LJ, Howitt BE, Fendler W, Stawiski K, Bu P, Cho L, i wsp. miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC). Journal of Clinical Oncology. 2017;35(15_suppl):e17116. doi:10.1200/jco.2017.35.15_suppl.e17116
  • Elias KM, Fendler WF, Stawiski K, Vitonis A, Berkowitz RS, Cramer DW, i wsp. Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer. Reproductive Sciences. 2017;24:87A.

Rekordy publikacji z Google Scholar

Tytuły i listy autorów podano tak, jak pokazuje je Google Scholar, wraz z liczbą cytowań. Pełny, zweryfikowany wykaz znajduje się powyżej.

Pokaż wszystkie rekordy (96)
  • B Tomasik, M Jąkalski, M Bieńkowski, J Teodorczyk, BK Sobocki, … Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics Journal of Translational Medicine 2026: 24 (1), 587 [cytowania: 3]
  • FLF Carvalho, J Lee, N Kalavros, Y Zhou, D Michaud, I Stelter, H Siddiqui, … Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer Cell Press Blue 2026: 1 (7) [cytowania: 3]
  • JW Webber, L Wollborn, S Mishra, S Alimena, B Testino, K Stawiski, … A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer Scientific Reports 2026: 16 (1), 14813 [cytowania: 0]
  • K Stawiski, L Kuncman, M Bilski, C Franzese, M Orzechowska, K Bułacz, … Association of Pre-Treatment Sacral Bone Marrow Morphology with Radiation-Induced Lymphopenia in Prostate Cancer International Journal of Radiation Oncology, Biology, Physics 2026: 126 (1), e635 [cytowania: 0]
  • K Stawiski, Z Nowicka, J Burzyński, N Jędrzejczak, A Zięba, … Baseline Lymphocyte Count Outperforms Dosimetry and Inflammatory Markers for Predicting Severe Radiation-Induced Lymphopenia in Rectal Cancer International Journal of Radiation Oncology, Biology, Physics 2026 [cytowania: 0]
  • B Tomasik, D Mikulski, BK Sobocki, K Kuna, A Papis-Ubych, K Stawiski, … Circulating microRNAs as prognostic biomarkers in patients with oropharyngeal cancer undergoing radiotherapy: temporal dynamics analysis Clinical and Experimental Medicine 2026 [cytowania: 0]
  • L Kuncman, K Stawiski, M Bilski, C Franzese, M Orzechowska, K Bułacz, … High-Throughput Dosimetric Profiling of Pelvic Organs at Risk and Lymphopenia in Prostate Radiotherapy International Journal of Radiation Oncology, Biology, Physics 2026: 126 (1), e595 [cytowania: 0]
  • K Stawiski, Ł Kuncman, M Jobczyk, M Bilski, C Franzese, M Orzechowska, … Pre-Treatment Sacral Bone Geometry Predicts Radiation-Induced Lymphopenia in Prostate Cancer Available at SSRN 2026: 6506353 [cytowania: 0]
  • W Majewski, M Bilski, W Kamzol, K Stawiski, G Majewski, K Konopa, … Renal Function Preservation after Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Multicenter Real-World Experience International Journal of Radiation Oncology, Biology, Physics 2026: 126 (1), e603 [cytowania: 0]
  • K Kuna, J Burzyński, D Mikulski, B Sobocki, A Papis-Ubych, K Stawiski, … Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy Contemporary Oncology/Współczesna Onkologia 2026: 30 (1), 33-39 [cytowania: 0]
  • K Stawiski, SC Kamran, J Perera-Bel, J Lee, J Bellmunt, KW Mouw, … Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review Briefings in Bioinformatics 2026: 27 (5), bbag487 [cytowania: 0]
  • K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere, J Lee, … Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma Molecular Oncology 2026: 20 (9), 2340-2355 [cytowania: 0]
  • M Golinska, A Rycerz, M Sobczak, J Chrzanowski, K Stawiski, W Fendler Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors-a network meta-analysis Frontiers in Immunology 2025: 16, 1619434 [cytowania: 14]
  • M Pajdziński, J Burzyński, A Zięba, N Jędrzejczak, J Fijuth, K Stawiski 4474 Risk of Neutropenia With or Without Daratumumab in Bortezomib-Based First-Line Chemotherapy and Radiotherapy for Multiple Myeloma: A Pilot Study Radiotherapy and Oncology 2025: 206, S919-S920 [cytowania: 0]
  • K Stawiski, A Rycerz, J Burzyński, K Kasper, W Fendler 4567 Radonek-Fine-Tuned GPT-4o for Radiation Oncology Patient Support: Preliminary Evaluation and Protocol for Prospective Validation Radiotherapy and Oncology 2025: 206, S2417-S2418 [cytowania: 0]
  • MM Pietrzak, W Pietruszewska, M Barańska, A Rycerz, K Stawiski, … Assessment of the Interdependencies Between High-Speed Videoendoscopy and Simultaneously Recorded Audio Data in Various Glottal Pathologies Biomedicines 2025: 13 (2), 511 [cytowania: 0]
  • D Chowdhury, KM Elias, W Fendler, K Stawiski Circulating microrna signatures for ovarian cancer US Patent 2025: 12,385,099 [cytowania: 0]
  • D Chowdhury, W Fendler, K Stawiski Circulating microrna signatures for pancreatic cancer US Patent App. 2025: 18/577,387 [cytowania: 0]
  • S Kołowacik, BJ Bińkowski, K Stawiski, J Drożdż Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation Polish Heart Journal (Kardiologia Polska) 2025: 83 (2), 203-206 [cytowania: 0]
  • K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere Rodero, J Lee, … Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma bioRxiv 2025: 2025.02.27.640395 [cytowania: 0]
  • Z Nowicka, K Kuna, M Łaszczych, M Łazar-Poniatowska, BK Sobocki, … Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques Physics and Imaging in Radiation Oncology 2024: 30, 100593 [cytowania: 14]
  • P Brady, A Yousif, N Sasamoto, AF Vitonis, W Fendler, K Stawiski, … Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use Frontiers in Reproductive Health 2024: 6, 1360417 [cytowania: 9]
  • K Stawiski, RT Fortner, L Pestarino, SU Umu, R Kaaks, TB Rounge, … Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches Frontiers in oncology 2024: 14, 1389066 [cytowania: 5]
  • A Puła, T Robak, I Dróżdż, K Stawiski, A Rycerz, M Misiewicz, P Robak Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens-pilot study Leukemia & Lymphoma 2024: 65 (2), 257-264 [cytowania: 4]
  • Z Nowicka, K Kuna, M Łaszczych, K Stawiski, B Tomasik, W Fendler Effect of the time-of-day of radiotherapy administration on radiation-induced lymphocyte depletion in lung cancer International Journal of Radiation Oncology, Biology, Physics 2024: 120 (2), e52 [cytowania: 3]
  • Z Nowicka, K Kuna, K Stawiski, J Sołek, M Świderek, A Papis-Ubych, … Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes Head & Neck 2024: 46 (2), E10-E17 [cytowania: 2]
  • JW Webber, L Wollborn, S Mishra, AF Vitonis, DW Cramer, RT Phan, … Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass Gynecologic oncology 2024: 190, 124-130 [cytowania: 2]
  • D Mikulski, M Nowicki, I Dróżdż, E Perdas, P Strzałka, K Kościelny, … MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation Biomarker Research 2024: 12 (1), 42 [cytowania: 1]
  • K Stawiski, M Bilski, J Nowak-Potemska, M Bilewicz, J Fijuth Radiation induced lymphopenia depends on lymph node irradiation in prostate cancer radiotherapy International Journal of Radiation Oncology, Biology, Physics 2024: 120 (2), e549-e550 [cytowania: 1]
  • M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth 1994: Predicting neutropenia dynamics after RT in first-line Bortezomib-based chemo for MM-a pilot study Radiotherapy and Oncology 2024: 194, S1165-S1168 [cytowania: 0]
  • K Stawiski, M Pajdziński, A Zięba, M Masłowski, J Fijuth 3178: Development of a CT-only autosegmentation model for hippocampal delineation in radiation therapy. Radiotherapy and Oncology 2024: 194, S3165-S3166 [cytowania: 0]
  • CJ Magnani, VD DAndrea, K Stawiski, I Stelter, T Hanlon, L Jia, AS Kibel, … AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior European Urology 2024: 85, S219-S220 [cytowania: 0]
  • F Mohammed, K Stawiski, HS Musa, SK Owolabi, S Abubakar, SO Rotimi, … Co-expression of HERV-R, CCND1, BRAF, FOXA1, TMPRSS2, ATF4 and low expression of BAZ1B and KMT2D is associated with early detection and poor prognosis of prostate cancer in … Cancer Research 2024: 84 (6_Supplement), 6432-6432 [cytowania: 0]
  • BA Łochowska, K Stawiski, K Kuna, Z Nowicka, M Łochowski, J Fijuth Predicting overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab-a Polish real-world single-center experience Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2024: 9 (3), 190-196 [cytowania: 0]
  • A Suleja, M Bilski, E Laukhtina, P Rajwa, K Stawiski, M Miszczyk Radioterapia stereotaktyczna (SBRT) w leczeniu pierwotnie zlokalizowanego raka nerkowokomórkowego (RCC)-przegląd systematyczny i metaanaliza Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY 2024: 9 (Suppl. 1) [cytowania: 0]
  • FLF De Carvalho, J Lee, K Bi, B Titchen, K Stawiski, J Park, A Garza, … Tumor-immune interactions and cisplatin resistance in localized muscle-invasive bladder cancer Cancer Research 2024: 84 (6_Supplement), 7041-7041 [cytowania: 0]
  • M Miszczyk, Ł Magrowski, T Krzysztofiak, R Stando, W Majewski, … Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group … Radiotherapy and Oncology 2023: 183, 109632 [cytowania: 32]
  • Y Zhou, J Börcsök, E Adib, SC Kamran, AJ Neil, K Stawiski, D Freeman, … ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer Science advances 2023: 9 (47), eadg2263 [cytowania: 29]
  • K Elias, U Smyczynska, K Stawiski, Z Nowicka, J Webber, J Kaplan, … Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles Nature communications 2023: 14 (1), 3350 [cytowania: 23]
  • Z Nowicka, B Tomasik, D Kozono, K Stawiski, T Johnson, D Haas-Kogan, … Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study Radiotherapy and Oncology 2023: 185, 109731 [cytowania: 19]
  • J Malinowski, W Pietruszewska, K Stawiski, MM Pietrzak, M Barańska, … High-speed videoendoscopy enhances the objective assessment of glottic organic lesions: a case-control study with multivariable data-mining model development Cancers 2023: 15 (14), 3716 [cytowania: 5]
  • M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy-a pilot study Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023: 8 (4), 274-283 [cytowania: 1]
  • K Stawiski, J Perera-Bel, A Rodriguez-Vida, NJ Rodero, KW Mouw, … Assessing tumor-infiltrating immune cells and outcomes with cisplatin-versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum … Journal of Clinical Oncology 2023: 41 (16_suppl), 4583-4583 [cytowania: 0]
  • M Jobczyk, K Stawiski, M Kaszkowiak, P Rajwa, W Różański, F Soria, … Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer European urology oncology 2022: 5 (1), 109-112 [cytowania: 41]
  • K Mieczkowski, K Kitowska, M Braun, B Galikowska-Bogut, … FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer Molecular Oncology 2022: 16 (15), 2823-2842 [cytowania: 23]
  • Ł Kuncman, M Orzechowska, K Stawiski, M Masłowski, M Ciążyńska, … The kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy suggests a potential gain from the earlier initiation of immunotherapy Cancers 2022: 14 (16), 3844 [cytowania: 18]
  • M Panek, K Stawiski, M Kaszkowiak, P Kuna Cytokine TGFbeta gene polymorphism in asthma: TGF-related SNP analysis enhances the prediction of disease diagnosis (a case-control study with multivariable data-mining model … Frontiers in immunology 2022: 13, 746360 [cytowania: 14]
  • K Stawiski, M Kaszkowiak, D Mikulski, P Hogendorf, A Durczyński, … OmicSelector: automatic feature selection and deep learning modeling for omic experiments BioRxiv 2022: 2022.06.01.494299 [cytowania: 11]
  • W Fendler, B Tomasik, K Atkins, K Stawiski, J Chałubińska-Fendler, … The clinician’s guide to radiotherapy complications Polskie Archiwum Medycyny Wewnętrznej 2022: 132 (1, art. ID 16190) [cytowania: 11]
  • A Gockley, K Pagacz, S Fiascone, K Stawiski, N Holub, K Hasselblatt, … A translational model to improve early detection of epithelial ovarian cancers Frontiers in Oncology 2022: 12, 786154 [cytowania: 8]
  • M Miszczyk, J Rembak-Szynkiewicz, Ł Magrowski, K Stawiski, … The prognostic value of PI-RADS score in CyberKnife ultra-hypofractionated radiotherapy for localized prostate cancer Cancers 2022: 14 (7), 1613 [cytowania: 8]
  • S Kubik, D Jesionek-Kupnicka, K Stawiski, J Fijuth, … Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma Journal of Obstetrics and Gynaecology 2022: 42 (6), 2248-2254 [cytowania: 6]
  • EJ Bobeff, M Bukowiecka-Matusiak, K Stawiski, K Wiśniewski, … Plasma amino acids may improve prediction accuracy of cerebral vasospasm after aneurysmal subarachnoid haemorrhage Journal of Clinical Medicine 2022: 11 (2), 380 [cytowania: 6]
  • EJ Bobeff, K Stawiski, PA Stanisławska, BJ Posmyk, K Wiśniewski, M Bryl, … Validation of the elderly traumatic brain injury score: observational case control study World neurosurgery 2022: 161, e464-e472 [cytowania: 5]
  • D Chowdhury, KM Elias, W Fendler, K Stawiski Circulating microRNA signatures for ovarian cancer US Patent 2022: 11,214,839 [cytowania: 3]
  • K Stawiski, M Maslowski, W Maslowska, M Kordzinska, B Lochowska, … Clinical and Radiomics-Based Deep Learning Predictive Model for Early Treatment Failure after Neoadjuvant Radiochemotherapy for Rectal Cancer International Journal of Radiation Oncology, Biology, Physics 2022: 114 (3), e150 [cytowania: 0]
  • A Napieralska, J Bochenek-Cibor, A Chyrek, M Konkol, E Pawłowska, … Improving Education in Radiation Oncology in Poland International Journal of Radiation Oncology, Biology, Physics 2022: 114 (1), e4-e5 [cytowania: 0]
  • D Mikulski, M Nowicki, I Dróźdż, E Perdas, P Strzałka, K Kościelny, … Serum miRNA-based neural network models for predicting complications in patients receiving high-dose melphalan or BeEAM conditioning chemotherapy. Acta Haematologica Polonica 2022: 53 (A), 66 [cytowania: 0]
  • M Miszczyk, J Ciepał, R Stando, O Masri, I Jabłońska, K Stawiski, … The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy International Journal of Radiation Oncology, Biology, Physics 2022: 114 (3), e231 [cytowania: 0]
  • M Miszczyk, E Staniewska, I Jabłońska, A Lipka-Rajwa, K Stawiski, … Volumetric staging in radiotherapy for oropharyngeal cancers Tumori Journal 2022: 108 (6), 586-591 [cytowania: 0]
  • P Robak, D Jarych, D Mikulski, I Dróżdż, E Węgłowska, A Kotkowska, … The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib Cancers 2021: 13 (5), 951 [cytowania: 23]
  • B Tomasik, A Papis-Ubych, K Stawiski, J Fijuth, P Kędzierawski, … Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy International journal of radiation oncology, biology, physics 2021: 111 (5), 1237-1249 [cytowania: 19]
  • M Panek, K Stawiski, P Kuna TGF-beta gene polimorphisms as risk factors for asthma control among clinic patients Journal of Inflammation 2021: 18 (1), 28 [cytowania: 14]
  • L Lee, B Howitt, T Cheng, M King, K Stawiski, W Fendler, D Chowdhury, … MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma Gynecologic oncology 2021: 163 (3), 453-458 [cytowania: 9]
  • D Mikulski, I Dróżdż, E Perdas, K Stawiski, M Nowicki, M Misiewicz, … Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation Blood 2021: 138, 4789 [cytowania: 5]
  • M Miszczyk, W Majewski, K Stawiski, K Rasławski, P Rajwa, I Jabłońska, … Prognostic factors in postoperative radiotherapy for prostate cancer-tertiary center experience Radiology and Oncology 2021: 55 (2), 203-211 [cytowania: 4]
  • Z Nowicka, R Bibik, R Stando, W Fendler, K Stawiski, B Tomasik A link between seasonality and radiation-related toxicity: The big time or time will tell? Radiotherapy and Oncology 2021: 161, 257-258 [cytowania: 2]
  • ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence BMC genomics 2021: 22 (1), 327-327 [cytowania: 1]
  • B Małachowska, B Tomasik, K Stawiski, S Kulkarni, C Guha, … Circulating microRNAs as biomarkers of radiation exposure: a systematic review and meta-analysis International Journal of Radiation Oncology, Biology, Physics 2020: 106 (2), 390-402 [cytowania: 73]
  • M Jobczyk, K Stawiski, W Fendler, W Różański Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC … Cancer medicine 2020: 9 (11), 4014-4025 [cytowania: 66]
  • Ł Kuncman, K Stawiski, M Masłowski, J Kucharz, J Fijuth Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer Strahlentherapie und Onkologie 2020: 196 (11), 998-1005 [cytowania: 30]
  • P Robak, I Dróżdż, D Jarych, D Mikulski, E Węgłowska, M Siemieniuk-Ryś, … The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients Cancers 2020: 12 (9), 2569 [cytowania: 28]
  • M Braun, D Piasecka, B Tomasik, K Mieczkowski, K Stawiski, A Zielinska, … Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma Cancers 2020: 12 (9), 2713 [cytowania: 18]
  • Z Nowicka, B Tomasik, DE Kozono, K Stawiski, TJ Johnson, … Serum Circulating MicroRNAs as Functional Biodosimeters in Patients Undergoing Total Body Irradiation International Journal of Radiation Oncology, Biology, Physics 2020: 108 (3), e536 [cytowania: 0]
  • Z Nowicka, K Stawiski, B Tomasik, W Fendler Extracellular miRNAs as biomarkers of head and neck cancer progression and metastasis International Journal of Molecular Sciences 2019: 20 (19), 4799 [cytowania: 47]
  • EJ Bobeff, J Fortuniak, B Bryszewski, K Wiśniewski, M Bryl, K Kwiecień, … Mortality after traumatic brain injury in elderly patients: a new scoring system World neurosurgery 2019: 128, e129-e147 [cytowania: 29]
  • A Zmyslowska, A Waszczykowska, D Baranska, K Stawiski, M Borowiec, … Optical coherence tomography and magnetic resonance imaging visual pathway evaluation in Wolfram syndrome Developmental Medicine & Child Neurology 2019: 61 (3), 359-365 [cytowania: 28]
  • M Kotlicka-Antczak, MS Karbownik, K Stawiski, A Pawełczyk, N Żurner, … Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state European Psychiatry 2019: 58, 72-79 [cytowania: 28]
  • M Zakrzewska, R Gruszka, K Stawiski, W Fendler, J Kordacka, … Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors BMC cancer 2019: 19 (1), 544 [cytowania: 19]
  • EJ Bobeff, BJ Posmyk, K Bobeff, J Fortuniak, K Wiśniewski, K Stawiski, … Predicting outcome and conservative treatment failure in patients with skull fracture after traumatic brain injury: a retrospective cohort study Journal of Neurological Surgery Part A: Central European Neurosurgery 2019: 80 (06 … [cytowania: 6]
  • L Kuncman, K Stawiski, M Maslowski, J Wilczynska, J Bury, J Fijuth FT3-L Dynamics in Blood Could be Predictive of Time of Occurrence Lymphocyte Nadir in Patients Undergoing Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics 2019: 105 (1), E167-E168 [cytowania: 0]
  • ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced … BMC genomics 2018: 19 (1), 37 [cytowania: 61]
  • K Pagacz, K Stawiski, A Szadkowska, W Mlynarski, W Fendler GlyCulator2: an update on a web application for calculation of glycemic variability indices Acta diabetologica 2018: 55 (8), 877-880 [cytowania: 38]
  • A Puła, K Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized … Leukemia & Lymphoma 2018: 59 (5), 1084-1094 [cytowania: 24]
  • K Stawiski, I Pietrzak, W Młynarski, W Fendler, A Szadkowska NIRCa: An artificial neural network-based insulin resistance calculator Pediatric Diabetes 2018: 19 (2), 231-235 [cytowania: 14]
  • KM Elias, W Fendler, K Stawiski, SJ Fiascone, AF Vitonis, RS Berkowitz, … Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer elife 2017: 6, e28932 [cytowania: 178]
  • J Trelinska, I Dachowska, D Baranska, K Stawiski, K Kotulska, W Fendler, … Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study) Pediatric blood & cancer 2017: 64 (6), e26347 [cytowania: 37]
  • K Stawiski, J Trelińska, D Baranska, I Dachowska, K Kotulska, S Jóźwiak, … What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods Magnetic Resonance Materials in Physics, Biology and Medicine 2017: 30 (4), 397-405 [cytowania: 9]
  • A Pula, K Stawiski, M Braun, E Iskierka-Jazdzewska, T Robak A systematic review and meta-analysis of B-cell receptor signaling inhibitors in relapsed and refractory chronic lymphocytic leukemia LEUKEMIA & LYMPHOMA 2017: 58, 152-153 [cytowania: 0]
  • A Puła, KG Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak Bezpieczeństwo i efektywność kliniczna nowych inhibitorów szlaku sygnałowego receptorów limfocytów B w leczeniu nawrotowej i opornej przewlekłej białaczki limfocytowej … Acta Haematologica Polonica 2017: 48 (Supl. 1) [cytowania: 0]
  • M Zakrzewska, W Fendler, K Stawiski, R Gruszka, K Zakrzewski, … Comparative Analysis of miRNA Expression in Pediatric Neuronal and Mixed Neuronal-Glial Tumors PEDIATRIC BLOOD & CANCER 2017: 64, S318-S318 [cytowania: 0]
  • LJ Lee, BE Howitt, W Fendler, K Stawiski, P Bu, L Cho, D Chowdhury, … miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC). Journal of Clinical Oncology 2017: 35 (15_suppl), e17116-e17116 [cytowania: 0]
  • KM Elias, WF Fendler, K Stawiski, A Vitonis, RS Berkowitz, DW Cramer, … Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer. REPRODUCTIVE SCIENCES 2017: 24, 87A-87A [cytowania: 0]
  • Ł Dziki, A Puła, K Stawiski, B Mudza, M Włodarczyk, A Dziki Patients’ awareness of the prevention and treatment of colorectal cancer Polish Journal of Surgery 2015: 87, 459-463 [cytowania: 15]
  • K Stawiski, A Strzałka, A Puła, K Bijakowski PancreApp: an innovative approach to computational individualization of nutritional therapy in chronic gastrointestinal disorders MEDINFO 2015: 2015: eHealth-enabled Health, 325-328 [cytowania: 10]
  • A Strzałka, K Stawiski, A Kaczmarek, A Kuchareczko, M Polguj, M Topol Analiza zmienności morfologicznych i topograficznych w zakresie struktur nerwowych i mięśniowych jamy pachowej (axillary fossa) w kontekście ich ewentualnych implikacji klinicznych Wydawnictwo Uniwersytetu Medycznego w Gdańsku 2013 [cytowania: 0]

Pełne rekordy publikacji: PubMed, ORCID, OpenAlex, Google Scholar.

Dydaktyka i wykłady na zaproszenie

Dydaktyka i opieka naukowa

Wykłady na zaproszenie

Oprogramowanie badawcze, projekty digital health i narzędzia

Narzędzia radioterapeutyczne i kliniczne

Oprogramowanie omiczne i biomarkerowe

Zdrowie cyfrowe

Działalność organizacyjna

Praca redakcyjna i recenzowanie

Członkostwo i działalność społeczna

Kursy certyfikowane

Kompetencje

Pobierz CV

Profil akademicki i pełne CV są dostępne po polsku i po angielsku, w formatach PDF i DOCX.

Profil akademickiZwięzłe naukowe CV do recenzji, współpracy i kontaktów instytucjonalnych.
Polski PDFPolski DOCXAngielski PDFAngielski DOCX
Pełne CV akademickieKompletny życiorys z pełnym wykazem publikacji i szczegółowym opisem działalności organizacyjnej.
Pełny PDF po polskuPełny DOCX po polskuPełny PDF po angielskuPełny DOCX po angielsku
Kontakt

Polska wersja CV została zaktualizowana 2026-11-07.

Copyright © 2026 Konrad Stawiski (konrad@konsta.com.pl). Built as OmicApp by Konrad Stawiski.